glucagon-like peptide 2 analogs (glp-2)

专利摘要:
glucagon-like peptide 2 analogs (glp-2) glp-2 analogs are disclosed which comprise one or more substitutions when compared to ah [gly2] glp-2 and which may have the property of a glp-2 activity. 1 altered, and its medical use. The analogues are particularly useful for the prophylaxis, treatment or amelioration of side effects of diabetes in the stomach and intestines.
公开号:BR112014027345A2
申请号:R112014027345
申请日:2013-05-03
公开日:2019-09-03
发明作者:Riber Ditter；Lindegaard Bovbjerg Kirsten；Just Rasmus；Shaun Russell Wayne
申请人:Zealand Pharma As；
IPC主号:

专利说明:

Descriptive Report of the Invention Patent for: “ANALOGS OF PEPTIDE 2 LIKE GLUCAGON (GLP-2)”.
Invention cameo (001] The present invention relates to analogues of glucagon-like peptide 2 (GLP-2) with altered GLP-1 activity and its medical use, for example, in the prophylaxis, treatment or treatment of diseases and attentions such as methoic endotoxemia, diabetes, obesity and the metahoic syndrome.
Background of the event [002] Low-grade inflammation is an independent risk factor for heart disease, stroke, diabetes and mortality. The research findings suggest that atheroselerosis, which involves the formation of fatty deposits ( plaques) and activity of free radicals and infectious agents in the arteries, can be compared to arthritis of the bones and joints due to the fact that both are inflammatory disorders. Inflammation precedes the detection of resistance to phsulin and, therefore, can be a good predictor of diabetes.
[Ü03] In addition, obese mice (ob / ob and db / db) have been shown to have impaired mucosal barrier function and increased systemic inflammation (Brun et a /., Am J Prtysfof GasPo / ntest Liver Physio / 292 : G518 -0525, 2007, October 5, 2006). These observations were also extended to C578L8 / J mice kept on a high-fat diet (Can! Et a /., DIABETES, VOL. 57, June 2008, p. 1470 to 1481) and to non-obese diabetic mice (Hadjiyanni atai. , 2009). Gani and colleagues, gut.bmj.com, 2009) reported that, in ob / ob mice, altering the intestinal microbiota reduced intestinal permeability and inflammation through a path directed towards GLP-2. In addition, the increased permeability seen in obese and diabetic patients is now more likely to have a more vital role in disease progression than had previously been anticipated. Increased intestinal permeability results in increased bacterial lipopolysaccharide (LPS) transport through the intestinal lumen.
2/66
This increased EPS activates immune cells, such as macrophages that circulate and are located in the body's organs, causing low-grade chronic inflammation involved in the pathogenesis of many diseases. This phenomenon is called metahúlic endotexemia (BD) and can be considered as a nine concept in the pathology of chronic diseases.
[004] Target ME and associated diseases are within the scope of this invention. Diseases that include type I diabetes mellifos, atherosclerosis, Parkinson's disease and cancerous metastasis arise in the context of low-grade chronic inflammation, the source of which has not been clearly defined yet. Interestingly, several recent studies have demonstrated significant correlations between levels of disease development and plasma endooxy (Chang 2011, J Med Sei 2011: 31 (5): 191 to 209).
[006] The hypothetical mechanism by which a double GLP2GLP1 agonist will work in a context of obesity diabetes is shown in Figure 1. The GLP2 component reduces inflammation and metabolic endotoxemia, while the GLP1 component provides glucose control and weight loss through classic GLP1-dependent mechanisms.
[006] Human GLP-2 is a 33-amino acid peptide derived from pfo-glucagon-specific translational processing in enteroendocrine L cells of the gut in specific brain stem regions. It is secreted along with glucagon-like peptide 1 (GLP-1), oxintomodulin and glycentin, in response to nutrient intake.
[007] GLP-2 Indus a significant growth of the small intestine mucosa epltéíiu by stimulating the proliferation of stem cells in the crypts and inhibiting apcpphosis in the villi (Drucker et al., Proo Nati Acad Sei USA 93: 7911 to 7916 (1996)), GLP-2 also has growth effects on the colon. In addition, GLP-2 inhibits gastric emptying and gastric acid secretion (Wojdemann et al., J Clin Endocrinol Metab. 84: 2513 to 2517 (1999)), improves intestinal barrier function (Benjamin et al., Gut47; 112 to 119 (2000)), stimulate the transport of intestinal hexose by regulating
3/66 positive of glucose transporters (Cheeseman, Am J Physiol R1965-71 (1997)), and increases intestinal blood flow (Guan et al., Gastroenterology125: 136147 (2003)).
[Ô68] GLP-2 binds to a single protein G-coupled receptor that belongs to the secretin-glucagon family cell. The GLP-2 receptor is expressed in the small intestine, colon and stomach, which are also local which are known to be responsive to GLP-2 (Yusta et al., Gastroenterology 119: 744 to 755 (2000)). However, the type of target cell for stimulation of the GLP-2 receptor in the gastrointestinal tract remains unclear, and the downstream intracellular mediators coupled to the GLP-2 receptor are not satisfactorily understood.
[009] The specific and beneficial effects of GLP-2 demonstrated in the small intestine have generated much interest in the use of GLP-2 in the treatment of intestinal injury or disease (Sinclair and Drucker, Physiology 2005: 357 to 365). In addition, GLP-2 has been shown to prevent or reduce damage to the mucosal epithelium in a large number of pre-cyclic models of intestinal ions, including chemotherapy-induced enthesis, ischemic and perfusion injury, dextran sulfate-induced colitis and genetic models of Inflammatory Bowel disease (Sinclair and Drucker Physiology 2005: 357 to 365). [916] Furthermore, the expression of GLP-2R MRNA in the stomach. (Yusta et al, 2000) combined with the observation that GLP-2 reduces gastric motility and gastric acid secretion (Meier et al, GASTROENTEROLOGY 2006: 130: 44 to 54) provides ample evidence that the stomach is directly or indirectly responsive to GLP-2. However, the use of GLP-2 or GLP-2 analogues in conditions distinguished by damage to the gastric lining has not yet been explored.
[011] GLP-2 is secreted with a 33 amino acid peptide with the following sequence His-Ala-Asp-Gly-Ser-Pha-Ser-Asp-Glu-Met-Asn-Thr-lleLeu-Asp-Asri-Leu -Ala-Ala-Arg-Asp-Phe-lle-Asn-Trp-Leu-lle-GIn-Thr-Lys-li-ThrAsp (SEQ ID NO; 1). It is rapidly ignited by the DPP IV enzyme in alanine
4/66 (Ala) at position 2 relative to the N-termini to form a human GLP-2 Inactive peptide (3-33). This rapid degradation of GLP-2 (1 -33), in addition to renal clearance, results in a half-life of about 7 minutes (Tavares et at, Am. 3 .. Physiol. Endocrinol. Pietab. 278: E134-E139 (2000)).
[012] The representative $ GLP-2 analogs are described, for example, in US Patent No. 5,720,379; 5,994,500; 6,184,201; 6,184,208; International publication n ^;> WO 97/39931; WO 01/41779; WO 02/066511 and DaQambra et al. (Biochemistry 2000. 39. 8888 to 8894), All references cited herein are expressly incorporated by reference in their entirety.
Summary of the invention [013] Broadly, the present invention relates to GLP-2 analogs that comprise one or more substitutions compared to wild-type GL.P-2 and which may have the property of a GLP- 1 modified, preferably increased, for example, as evaluated in m wfro efficacy tests. GLP-1 activity, for example, can be measured by determining the EC5Q values at the GLP-1 receptor as lower than those for native GL.P-2. In some embodiments, the GLP-2 analogs of the invention comprise one or more substitutions at an amino acid position corresponding to one or more of positions 2, 3, 5, 7, 8, 9. 10, 11, 12, 14, 15 , 16, 19, 20, 21 _; 24, 27 and / or 28 of the wild-type GLP-2 sequence in combination with Gin, Lys or Glu at position 17. In some embodiments, the GLP-2 analogs of the invention comprise one or more substitutions at an amino acid position corresponding to one or more of positions 2, 3.5, 7, 8, 9, 10, 11, 12, 15, 16, 20, 21, 24, 27 and / or 28 of the wild-type GLP-2 sequence in combination with Gin, Lys or Glu at position 17. In some embodiments, the GLP-2 analogs of the invention comprise a conservative or non-conservative substitution at position 2 and / or a substitution or deletion of one or more of the amino acids corresponding to an amino acid from positions 28 to 33 of the wild-type GLP2 sequence. In some embodiments, the GLP-2 analogs of
5/66 the present invention optionally comprise lipophilicus substituents conjugated to one or more of positions 12, 14,16,17,19, 20, 24,27, 28 and 32. In some embodiments, the GLP'2 analogs of the present invention comprise optionally iipophilic substituents conjugated to one or more of the positions 12,16, 17, 20, 24, 27, 28 and 32.
[014] In some embodiments, a GLP-2 analogue is represented by the General Formula I:
R ¹ -His ~ X2-X3-Giy-X5-'Phe ~ X7-X8-X9 ~ Xl 0-X11 -X12-X13-X14-X15XI 7-Wing ~ X19-X20-X21 -Phe-He-X24- Trp-Leu-X27-X28-X2S-X30-X31 -X32-X33R ³ (SEQ ID NO 2) or a pharmaceutically acceptable salt or solvate thereof, where:
R ^; è hydrogen, O- _: .4 alchemy (for example, methyl), acetyl, formüa, benzoyl or trifiuoroacetyl;
X2 is Gly _s Ala or Aib:
X3 is Glu, Gin or Asp;
X5 Ser or Thr;
X7 Ser or Thr;
X8 is Asp, Glu or Ser;
X9 is Glu or Asp;
XI0 is Met, Vai. Leu or Tyr;
X11 is Asn, Ser or Ala;
XI2 is Thr, Ser or Lys;
XI3 is He. Read, Val, Tyr, Phe or Gin;
X14 is Leu or Mat;
XI5 is Asp or Glu;
XI6 is Asn, Gin, Gly, Ser, Ala, Glu or Lys;
X17 is Gin, Lys, Arg, His or Glu;
X19 is Ala or Vai;
X20 is Arg, Lys or His;
β / 66
Χ21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys;
X27 is He, Leu, Vai, Glu or Lys;
X28 is Gin, Asn, Lys, Ser, Y1 or absent;
X29 is Thr, Y1 or absent;
X30 is Lys, ¥ 1 or absent:
X31 is He, Pro or absent;
X32 is Thr, ¥ 1 or absent:
X33 is Asp, Asn, ¥ 1 eu absent;
Y1 is Gly-Gly-Pro-SerSer-Gly-Ala-Pro-Pro-ProSer, or Lys-Asn-GlyGty-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; and
R ^s is NH _S or OH;
provided that the Formula I GLP-2 hook is not
HGDGSPSDEMNTILDGQAARDFINWLIQTKITD; (SEO ID NO 3)
HGDGSFSDEMNTÍLDNQAARDFINWLIQTKITD; (SEQ ID NO 4) or
HGDGSFSDEMNTILDSQAARDFINWLIQTK (SEQ ID NO 5) [013] In this formula, X31 can also be ¥ 1. X28 can also be Gly. X29 can also be Wing.
[918] In addition, Y1 can be present between X33 and R ^{: í} . Then, a position X34 could be contemplated, where X34 is Y1 or is absent.
[017] In some embodiments, a GLP-2 analog is a GLP-2 analog, according to Formula I or a pharmaceutically acceptable salt or solvate thereof, where:
R ^! it's hydrogen,
X2 is Gíy, Ala uu Aib;
X3 is Glu, Gin uu Asp:
X5 is Ser or Thr;
X7 is Ser or Thr;
X8 is Asp, Glu or Ser;
7/66
X9 is Glu or Asp:
X10 is Met, Vat Leu or Tyr;
X11 is Asn, Ser, or Ala;
ΧΊ 2 is Thr or Lys;
X14 is Leu or Met
X15 is Asp au Glu;
X16 is Ash, Gin, Gly, Ser, Ala, Glu or Lys;
X17 is Gin or Lys;
X19 is Ala or Vai;
X20 to Arg, Lys or His;
X21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys;
X27 is Ila, Leu, Vai or Lys:
X28 is Gin, Asn, Y1 or absent;
X29 is Thr, ¥ 1 or absent;
X30 is Lys, Y1 or absent;
X31 is lie, Pre, Y1 or absent;
X32 is Thr, Y1 or absent;
X33 is Asp, Asn, Y1 or absent;
¥ 1 is “Gly-Gly-Pro-SerSer-Gly-Ala-Pro-Pro-Pro-Ser;
The
R ' ^: is _NH; or OK as long as the Formula I GLP-2 analogue is not
HGDGSFSDEMNTILDGQAARDFINWLIQTKITD;
HGDGSFSDEMNTILDNQAARDFINWLIQTKITD; or HGDGSFSDEMNTILDSQAARDFINWLIQTK.
[018] In this formula, X13 could be Ila, Leu, Vai, Tyr, Phe uu Gin [018] X28 could also be Gly. X29 can also be Wing. ¥ 1 could be present between X33 and R ² [020] In some modalities, X14 of Formula 1 is Leu.
8/66 (021] In some modalities, Xi 4 of Formula I is Mat [022] In some modalities XI7 of Formula I is Gin, [023] In some modalities, XI7 of Formula I is Lys.
[024] In some modalities, X17 of Formula 1 is Glu.
[025] In some modalities, X19 of Formula I is Ala. [026] In some modalities, X19 of Formula I is Vai, (027] In some modalities, X16 of Formula I is Gly and X17 of Formula
I'm Gin.
[028] In some modalities, X16 of Formula I is Gly and X17 of Formula I is Lys.
[029] In some cases, XI6 of Formula I is Gly and X17 of Formula I is Glu, [030] In some modalities, X2 of Formula I is Aid, X16 of Formula I is Gly and X17 of Formula I is Gin.
[031] In some embodiments, X2 of Formula I is Alb, XI6 of Formula I is Gly and XI7 of Formula I is Lys.
[032] In some modalities, X2 of Formula I is Alb, X16 of Formula I is Gly and Xi of Formula I is Glu.
[333] In some modalities, X2 of Formula I is Gly, Xi 8 of Formula I is Gly and XI7 of Formula I is Gin.
(034] In some modalities, X2 of Formula I is Gly, X16 of Formula I is Gly and XI7 'of Formula a is Lys, [636] In some modalities, X2 of Formula I is Gly, X16 of Formula I is Gly and XI7 of Formula I is Glu, [036] In some embodiments, a GLP-2 analogue is represented by General Formula 1a:
[037] R'-His-X2-X3'G! Y-X5-Phe * X7-X8 ~ X9-X10 ~ X11 -X12-X134..euX15XI6-X17-Ala-Ala-X20-X21 -Phedfe-X24 -Trp <eu-X27-X28-X29-X30-X31 -X32X33-R ² (Ia) (SEO ID NO 6) [038] or a pharmaceutically acceptable or wild salt thereof,
9/66 [03S] where:
[040] R 'is hydrogen, C _w alkyl (e.g., methyl), acetyl, forrnyl, benzoyl or trifluoroacetyl;
X2 is Gly, Ala or Atb;
X3 is Glu, Gin or Asp;
X5 is Ser or Thr;
X is Ser or Thr;
X8 is Aso, Glu or Ser;
X9 is Glu or Asp;
XI0 is Met, Vai, Leu or Tyr;
X11 is Asn or Ser;
XI2 is Thr, Ser or Lys;
XI3 is He ,. Read, Val, Tyr, Phe or Gin;
X15 and Asp or Glu;
X16 is Aso, Gin, Gly, Ser, Ala, Glu or Lys;
XI7 is Gin, Lys, Arg, His or Glu;
X20 is Arg, Lys or. Hist
X21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys:
X27 is He, Leu, Vai, Glu or Lys:
X28 is Gin, Asn, Lys, Ser, Y1 or absent;
X29 is Thn Y1 I absent;
X30 is Lys, Y1 or absent;
X31 is He, Pre or absent;
X32 is Thr, Y1 or absent;
X33 is Asp, Asn, Y1 or absent;
Y1 is Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser, or Lys-Asn-Gly ··
Gly-Pru-Ser-SerXSIy-Ala-Pro-Pro-Pru Ser; and R is NR; or OH;
provided that the Formula Ia GLP-2 analogue is not
10/86
HGDGSFSDEMNTILDGQAARDFINWUQTKITD;
HGDGSFSDEMNTILDNQAARDFINWLIQTKITD; or HGDGSFSDEMNTILDSQAARDFINWLIQTK.
In that formula. X31 can also be Y1.
[041] In addition. Y1 can be present between X33 and Ra Then, a position X34 can be contemplated, where X34 is naked Y1 is absent.
[042] X28 can also be Gly. X29 can also be Wing.
[043] In some embodiments, a GLP-2 analogue is an analogue of
GLP-2, according to Formula Ia or a pharmaceutically acceptable or salvate salt thereof, wherein;
R 'is hydrogen,
X2 is Gly, Ala or Aid;
X3 is Glu. Gin or Asp;
X5 is Ser or Thr;
X7 is Ser or Thr;
X8 is Asp, Glu or Ser;
X9 is Glu or Asp;
XI0 is Met, Vai, Leu or Tyr;
X11 is Asn I Ser;
X12 is Thr or Lys;
X1S is Asp or Glu;
X16 is Asn, Gin, Gly, Ser, Ata, Glu or Lys;
XI7 is Gin or Lys;
X20 is Arg. Lys or His;
X21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys;
X27 is He, Leu, Val or Lys;
X28 and Gin, Asn, Y1 or absent;
X29 is Thr, Y1 or absent;
11/66
X30 is Lys, ¥ 1 or absent;
X31 is He, Pro, ¥ 1 or absent:
X32 is Thr, ¥ 1 or absent;
X33 is Asp, Asa, ¥ 1 or absent;
¥ 1 is Gly-Oly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; and
R ^s is NHz or OH;
provided that the analog of Formula Ia is not
HGDGSFSDEMNTILDGQAARDFINWLIQTKITD: HGDGSFSDEMNTILDNQAARDFINWUQTKITD-.or HGDGSFSDEMNTILDSQAARDFINWUQTK.
[644] In this formula, XI3 can be He. Read, Go, Tyr. Phe or Gin,
X28 can also be Giy. X29 can also be Ala, ¥ 1 can be present between X33 and R ^;
In some modalities, X17 of Formula Ia is Gin, In some modalities, X17 of Formula Ia is Lys. In some embodiments, Formula Ia's X17 is Glu.
In some modalities, XI6 of Formula Ia is Giy and XI7 of Formula Ia is Gin,
In some embodiments, X16 of Formula Ia is Gly and X17 of Formula Ia is Lys.
In some embodiments, X16 of Formula Ia is Giy to X17 of Formula Ia is Glu.
In some modalities, X2 of Formula Ia is Alb, X16 of Formula Ia is Gly, X17 of Formula Ia is Gin,
In some embodiments, X2 of Formula (a is Aib. X16 of Formula Ia is Gly and X17 of Formula Ia is Lys.
In some embodiments, X2 of Formula 1a is Aib, XI6 of Formula Ia is Gly and XI7 of Formula Ia is Glu.
In some modalities, X2 of Formula Ia is Giy, X16 of Formula
12/66 la is Gly the XI7 of Formula la is Gin.
In some modalities, X2 of Formula la is Gly, XI6 of Formula la is Gly to XI7 of Formula la is Lys,
In some modalities, X2 of Formula la is Gly, XI6 of Formula la is Gly and XI7 of Formula la is Glu.
In any of the above embodiments, or independently, X8-X9-X10-X11 may be Ser-Glu-Leu-Ala.
(045] In the generic formulas described above, the positions X28 to X33 can be selected from certain amino acid residues, or they can be Y1, or they can be absent. It is intended that the GLP-2 arrelogo contains no more than a chemical portion of ¥ 1 and that, if present, ¥ 1 forms the C-terminal part of the molecule, so if any of the positions X28 through X33 is ¥ 1, all downstream positions are absent; that is, those positions X29 to X33 (or X34) downstream of that ¥ 1 are absent). In this context, the "downstream ¹¹ " positions of a given position are those located at the C-terminal of that position.
[046] Furthermore, if any of the positions X28 to X33 are absent, then all positions downstream from that position are also absent (except for the fact that Y1 may be present). So, the only combinations of those positions that ask to be absent are X33; X32 -33; X31-X32-X33; X30-X31-X32-X33: X29-X30-X31-X32-X33; and X28 - X29-X30-X31 X32-X38. Otherwise, if the XN position is present (where N is an integer between 28 and 33), then the X position (N-1) is also present, [047] The GLP-2 analog can be represented by General Formula II: R'-His-X2-X3 ^ y'-X5-Phe-X7-Ser-Glu ~ Leu-AlteXl 2-X13-X14-X15X16-X17-Ala-X19 ~ X20-X21 -Phedíe- X24-Trp-leu-X27-X28-X29-X30-X31 -X32X33 ~ X34 ~ R (II) (SEQ ID NO 7) or a pharmaceutically acceptable salt or solvate thereof, wherein;
Fp is hydrogen, G <. << alkyl (eg methyl), acetyl, formlla,
13/66 benzoOa au trifluoroacetlla;
X2 is Gly, Ala or Aib:
X3 is Glu, Gin i Asp;
X5 is Ser au Thr;
X7 is Ser cu Thr;
X12 is Thr, Ser au Lys;
XI3 is lie, Leu, Val, Tyr, Phe or Gin;
X14 is Leu or Met;
XIS is Asp cu Glu;
XI6 is Gly, Ser, Ala, Glu au Lys;
XI7 is Gin or Lys;
XI9 is Ala eu Vai;
X20 is Arg, Lys au His;
X21 is Asp, Glu au Leu;
X24 is Asn, Ala, Glu au Lys;
X27 is He, Leu, Vat Glu or Lys;
X28 is Gin, Asn, Lys. Ser, Gly. YI or absent;
X29 is Thr, Ala, YI or absent;
X30 is Lys, Y1 or absent:
X31 is He, Pro, Y1 or absent;
X32 is Thr, YI or absent;
X33 is Asp, Asn, Y1 or absent;
X34 is ¥ 1 au missing:
¥ 1 is Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pra-Pre-Ser, or Lys Asn GlyGly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; and
R ^s is NH _S or GH: wherein the GLP-2 analog contains no more than one Y1;
if any of X28 to X33 far ¥ 1, those positions X29 to X34 downstream from that Y1 are absent:
if any of X28 to X33 is absent, those positions
14/66
X29 to X33 downstream from those positions are also absent.
[648] In some modalities, X16 of Formula II is Gly, Ser or Ala. In such modalities, X17 of Formula II may be Lys, or XI7 of Formula II may be Gin, [049] Still further or alternatively, X2 of Formula II may be Gly or Ala.
[050] So, in some modalities, X16 of Formula II is Gly and X17 of Formula II is Gin.
[051] In some modalities, X16 of Formula H is Gly and X17 of Formula li is Lys.
[052] In some modalities, X2 of Formula II is Gly, X16 of Formula II is Gly and X17 of Formula H is Gin.
[053] In some modalities, Formula II's X2 is Gly. XI6 of Formula II is Gly and X17 of Formula II is Lys.
[054] In some modalities. X2 of Formula II is Aíb, X16 of Formula II is Gly and XI7 of Formula II is Gin.
[G55] In some embodiments, X2 of Formula II is Alb, X16 of Formula II is Gly and X17 of Formula H ó Lys.
[056] So, in some Formula B modalities:
R 'is hydrogen, C 6 alkyl (for example, methyl), acetyl, formyl, benzoHa or trfluoroaceilla;
X2 is Gly or Alb;
X3 is Glu or Asp;
X5 is Ser or Thr;
X7 is Ser or Thr;
XI2 is Thr, Ser or Lys;
XI3 is lie, Leu, Val, Tyr. Phe or Gin;
XI4 is Leu or Met:
X15 is Asp or Glu;
X16 is Gly, Ser or Ala;
15/68
XI7 is Gin or Lys;
Xi 9 is Wing or Vai:
X20 is Arg, Lys or Hls:
X21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys;
X27 is ite, Leu, Vai Glu or Lys;
X28 is Gin, Asn, Lys, Ser, Gly, Y1 or absent:
X29 is Thr, Ala, Y1 or absent;
X30 is Lys, ¥ 1 or absent;
X31 is lie, Pro, ¥ 1 or absent;
X32 is Thr, ¥ 1 or absent;
X33 is Asp, Asn, ¥ 1 or absent;
X34 is ¥ 1 or absent;
¥ 1 is Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pm-Pm-Ser _; or Lys-Asn-GiyGly-Pro-Ser-Sor-Gly-Ala-Pro-Pro-Pro-Ser; and is NH _S or OH; pm that the GLP-2 analog contains no more than one ¥ 1;
if any of X2S to X33 is ¥ 1, those positions X29 to X34 downstream of that ¥ 1 are absent;
if any of X28 to X33 is absent, those positions X29 to X33 downstream from that position are also absent.
In some modalities, XI6 is Giy and X17 is Gin.
In some embodiments, XI6 is Giy's X17 is Lys.
In some modalities, X2 is Gly, X16 is Giy and X17 is Gin.
In some modalities, X2 is Giy. XI6 is Gly and XI7 is Lys.
In some modalities, X2 is Alb, X16 is Gly and X17 is Gin.
In some modalities, X2 is Aíb, X16 is Gly and X17 is Lys.
In some embodiments, a GLP-2 analogue is represented by General Formula III:
R ' ⁱ -His-Giy-X3-Gly-X6-Phe-X7-Ger-Glu-Leu-.Aia-Xi 2-X13 ~ Leu ~ X151S / 66
Gly-X17 ~ Ala - Xl 9-X2CHX21 -Phe-lle-X24-Trp <eu-X27-X23 - X29-X30-X31 -X32Χ33-Χ34-ΤΓ '(HI) (SEQ ID NG 21) or one pharmaceutically acceptable salt or solvate thereof, where:
R- is hydrogen, C © alkyl (for example, methyl), acetyl, formula, benzolla or trluoreacetlla;
X3 is Glu or Asp;
X5 is Ser or Thr:
X7 is Ser or Thr;
X12 is Thr, Ser or Lys;
XI3 is He, Tyr, or Gin;
XI5 is Asp or Glu;
X17 is Gin or Lys:
XI9 is Ala on Vai;
X20 is Arg, Lys or His;
X21 to Asp, Glu or Leu;
X24 is Asm Ala, Glu;
X27 is He, Leu, Glu or Lys:
X2S is Gia, Lys, Ser, Gly, ¥ 1 or absent;
X29 is The Wing, ¥ 1 or absent;
X30 is Lys, ¥ 1 or absent;
X31 is He, Pro, ¥ 1 me missing:
X32 is Thr, ¥ 1 eu absent;
X33 is Asp, Asn, ¥ 1 or absent;
X34 is ¥ 1 or absent:
¥ 1 is Gly-Gly-Pro ~ Ser ~ Ser ~ Gly-Ala-Pro ~ Pro ~ Pro-Ser, or Lys-Asn-GlyGly - PrO'-Ser-'Ser ~ Gly-Ala-Pro-Pro-Pro -Ser: e
R ^$: 'é or OH: where the GLP-2 analogue contains no more than one Y1;
if any of X28 to X33 is ¥ 1, those positions X29 to
X34 downstream daggers Y1 are absent;
if; anyone> out of Χ2β to X93 is absent, those bags X: <$ to K33 downstream çaqueia pmsiçáu also astác absente.
[057] g $ any of the above modalities, pruning w desirable so that the amino acid sequence of the GLPdr analog does not have more than 6 amU & aide changes, for example, as half as 4. no more than 3. no more than 3 or no more than 1 alteration of the amino acid sequence. HGDGSFSSELATlLDG ^ XARDFiNWüOlKíTD · or HGDOSFSSÊtÁOLDGQAARDFfÂWLIQTKITD.
[953] In some ways a GLP-2 analog of mvmnçâs is represented by any of the following sequences:
H ^^ DGEFÉDEMN11íd3NDAARDFINVVLlGl'KI'rD: iSEÜ ID N0 8} HGDGSFSDEMNT1LDNKAARDF INWLIGTKITD; (EEQ ID NO 9) HGGGSFSGEMNTILODGAARDFINWL1QTK, (SEG ID NO 10} $ HGDGSFS EMNTIL.D3QAADDFimdJGTKITD; (SEQ 10 NO HGEGTFTSÜLSKQMEGQAyRDFlEWlIQTKlTD} li: (SEQ ID NO 10) ^ HGEGTFTSÜLSKQMESK ARDFIEAIIQTKÍTD: (SBQ ID NO 13) ^ HODGSFSSELATlLDCy ARDFINVVtrDTKíiD; (SEO ID NO U) ρίΟΕ ^ ΤΕΤβΟ18ΤϊΙΕΝΚΜΒΟΕΙΒνΕίΟΤΚΙΤΟ: {SEQID NO 15) HGEG $) FSSDLSTH.ENKM.RGFIEWUQTkiTD: (8EO ID NO 16) HxAi ^ DGSFSDELNTiLDGKAARpFINWUQTK; {GEQ ID NO 17) hGDGSFSSELATIIDGQAARDHAWÍJQTKITD: {8EOID.no 16) HGDfòSFSDEMNTiLDGQAARDFíNWÚIDTK; (SEQ ÍD NO 19} a HQÉGSFSSDLSTILEGKAARDFIEVVUDTKDD; (SEO ID NO 30) or an acceptable family salt I am the same ..
[ú53] Of this measure, the analog of GuP onmptW R'Z-Ft cm which Γ <the R * is the one defined in the generic formulas to Z is a sake of the peptides efafacionados of those listed above.
[363) In some modalities, a QLP-S sample from jnvanpáo onmpende a subliminal iipgfíllcc conjugated to an amino acid in one of mveap & m> ca> be a
18/66 position corresponding to one or more of positions 12, 14, 16,17,19, 20, 24, 27. 28 and 32 of the native GLP-2, [061] In some embodiments, a GLP-2 analogue of the The invention comprises an Hpophilic substituent conjugated to an amino acid in a position corresponding to one or more of positions 12, W, 17, 20, 24, 27, 28 and 32 of the native GLP-2.
[0S2] In some embodiments, a GLP-2 analog of the invention can be used in a therapy.
[063] In some embodiments, the invention provides a pharmaceutical composition comprising a GLP-2 analogue of the invention, or a salt or derivative thereof, in admixture with a carrier. In some embodiments, the pharmaceutical composition may comprise a GLP-2 analog which is a pharmaceutically acceptable acid addition salt. In some embodiments, the pharmaceutical composition is formulated as a liquid suitable for administration by injection or infusion, or is formulated so as to cause the slow release of a GLP-2 analog of the invention.
[064] In some embodiments, the invention provides the use of a GLP-2 analogue of the invention for the preparation of a medicament for the treatment and / or prevention of low-grade inflammation.
[Ô65] In some embodiments, the invention provides the use of a GLP-2 analogue of the invention for the preparation of a medicament for the treatment and / or prevention of low-grade inflammation related to diabetes (which may be type I diabetes) or type II, however, typically, type II). In some embodiments, low-grade inflammation is local or systemic low-grade inflammation. In some embodiments, low-grade inflammation includes metabolic syndrome, obesity (eg, abdominal obesity), diabetes, heart disease, gastrointestinal inflammation, depression, Alzheimer's, arthritis, hypertension, dyslipidemia and stroke, gastrointestinal disorders in the gastrointestinal tract upper esophagus, stomach, duodenum, small intestine, colon and rectum, including ulcers of
19/66 any etioiogla (for example, peptic ulcers, Zollinger-Ellison's syndrome, drug-induced ulcers, infection-related ulcers or other pathogens), digestive disorders, malabsorption syndromes, short bowel syndrome, cul-de-sac syndrome , bowel inflammatory disease (eg, Crohn's disease and ulcerative oolitis), celiac sprue (eg, due to gluten-induced anteropathy in celiac disease), tropic sprue, hypogammaglobulinemia sprue, and chemotherapy-induced mucositis and diarrhea and / or radiation-hemotherapy. Some of the above disorders, diseases and conditions can be characterized by being associated with low-grade inflammation.
[066] In some embodiments, the invention provides a nucleic acid molecule that comprises a nucleic acid sequence encoding a GLP 2 analogue of the invention, [667] In some embodiments, the invention provides an expression vector that comprises a molecule nucleic acid sequence comprising a nucleic acid sequence encoding a GLP-2 analog of the invention in combination with control sequences to direct the expression of the GLP-2 analog. In some embodiments, the invention provides a host cell transformed with the expression vector.
[668] In some embodiments, the Invention provides a method for producing a GLP-2 analog of the invention, the method comprising culturing host cells that express the GLP-2 analog under conditions suitable for expression and purifying the GLP analog -2 then produced.
[069] In some embodiments, a nucleic acid molecule of the invention, an expression vector of the invention or a host cell of the invention can be used in a therapy.
[670] In some embodiments, the invention provides the use of a nucleic acid molecule of the invention, an expression vector for. invention or a host cell of the invention in the preparation of a medicament for the treatment and / or prevention of low-grade inflammation. In some
20/66 modalities, low-grade inflammation is local or systemic and may include, for example, metabolic syndrome (broadest possible definition), obesity (eg, abdominal obesity), diabetes, heart disease, gastrointestinal inflammation, depression, mal Alzheimer's disease, arthritis, hypertension, dyslipidemia and stroke, gastrointestinal disorders in the upper gastrointestinal tract of the esophagus, stomach, duodenum, small intestine, colon and rectum, including ulcers of any etiology (for example, peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, infection-related ulcers or other pathogens), digestive disorders, malabsorption syndromes, short bowel syndrome, oul-decr syndrome, intestinal fl ammatory disease (Crohn's disease and ulcerative oolitis) , celiac sprue (e.g., due to gluten-induced enteropathy or oe.haca disease), tropic sprue, hypogammaglobulinemic sprue, and mucositis and diarrhea induced by chemotherapy and / or radiation-hemotherapy.
[071] In some embodiments, the invention provides a method for treating a gastrointestinal disorder (e.g., stomach or intestine) in a patient who needs it by administering an effective amount of a GLP-2 analog of the invention, a molecule nucleic acid of the invention, an expression vector of the invention or a host cell of the invention. In some embodiments, the gastrointestinal disorder is low-grade inflammation. Can low-grade inflammation become local or systemic and may include methadone syndrome, obesity (for example, abdominal obesity), diabetes, heart disease, gastrointestinal inflammation, depression, Alzheimer's, arthritis, hypertension, dyslipidemia and stroke, gastrointestinal disorders in the upper gastrointestinal tract of the esophagus, stomach, duodenum, small intestine, colon or rectum, including ulcers of any etiology (for example, peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, infection-related ulcers or other pathogens), digestive disorders , malabsorption syndromes, short bowel syndrome, cul-disable syndrome. inflammatory bowel disease in the axsmpiu _; Grahn's dengue and ulceralivab thing to sprue (& x example of anierup & aia induced by giuten or nedaca disease), sprue ess trapses, sp-ue hípDgamagiDbútámmioa. muocsita the diarrhea induced by chemotherapy and / or radiation-hemotherapy> [072] In some modalities, the injection provides a therapeutic kit that comprises a chemotherapy drug for cancer to a GLP-2 analogue of the invention, a water molecule. nucleicu of the invention. an expression vector of the invention or a host cell of the invention, each npnionmmsate ç-m òomhíuáçúD with in nônendvx farmaúnstk: amenis auòííétféL [073] Figure 1 shows the ALFs of GLFM and GLP-2 in physiological trajectories. {Adapted from Oani et au, Pharmacology and Therapeutics i.3O (20t0 ^ 2a'212i.)
• yS. '·. ·: Íw àjXí> λ Tp: iSr>: * s ·::> c < rX i ^h <cfr / Xit »· > * í> i »- * SV > X << · í >>> VA J ‘X * SA“ - / ^ Α'-ίΫχ · ΐρΧ ·> “ί £> Λ ·» “·:: 7Λ> λ ·. · Αϊ · λ · x mgwíiS a, rnosuo ν ' ft ξίϊνηυϊ * Πςί <r.Jf fíiOíSí rei cm <, << m pUS ^ O> X ΐ> 0 do · νο ícukí in the test toti pray Sandia à : giieus e (HQ3 ~ T). One ho ra before du
In a glucose test, measurements of basin puncture obtained when Compound 12 / wuul was administered. (Aj Glucose levels in blood during the trial period (B) AUG of blood glucose measurements, (075j Figure 3 shows the effects of the administration of Compound 7 and the vehicle on the intestinal wet weight. The animals were shot with the compound 7 or the vehicle had a leak during four days in the d & G the small intestine has been removed or posada {rWJ Figure 4 shows the ofaitus of the administration of the two week test oompusto 7 or of the administration of the vein in the intestinal weight
AI)
Wet paste of the intestine (B) Wet weight of the intestine rages.
(S77J Figure 5 shows the effects of administering bare .week- test compound 7 or administering the vehicle on gypsum homeostasis,
The animals live in fast from one day to the next, the blood was extracted for analysis of (A) icicose in blood in jeiam (B) insulin piasmãtíoá ^; 66 fasting and (0) evaluation of the homeostatic model of insulin resistance (HOMA-IR),
Detailed description of the invention [078] Unless otherwise defined herein, the scientific and technical terms used in this application should have the meanings that are commonly understood by those of ordinary skill in the art. In general, the nomenclature used in conjunction with, and the techniques of, chemistry, molecular biology, cell and cancer biology, immunology, microbiography, pharmacology, and protein and nucleic acid chemistry described herein is that well known and commonly used in the art.
[078] All publications, patents and published patent applications cited in this application are now specifically incorporated by reference. In case of conflict, this specification, including its specific definitions, will prevail.
[080] Each embodiment of the invention described herein can be considered by itself or in combination with one or more other embodiments of the invention. Definitions [081] Unless otherwise specified, the following definitions are provided for specific terms, which are used in the written description above.
[082] Throughout this specification, the word understand or variations, such as “understands or“ understands, will be understood to imply the inclusion of a particular integer (or components) or group of integers (or components) however, not excluding any other whole number (or components) or group of whole numbers (or components), [083] The singular forms one, one, o and “a include plurals, unless the context clearly indicates the contrary.
[084] The term inclmrw is used to mean “including, but not limited to. Including ³ and including, but not limited to, are used in
23/66 alternate mode.
[OSS] The terms''patient ¹ '. subject and ^:: individual ask to be used alternately and refer to a human being or a non-human animal. Such terms include mammals, such as humans, primates, cattle (for example, cattle, pigs), domestic animals (for example, dogs, cats) and rodents (for example, mice and rats).
[086] The term solvate ¹¹ in the context of the present invention refers to a complex of defined stoichiometry formed between a solute (fn case, a peptide conjugate or pharmaceutically acceptable salt thereof, according to the invention) and a solvent, O solvent in that connection can be, for example, water, ethanol or other typically small and pharmaceutically acceptable molecular organic species, such as, but without limitation, acetic acid and lactic acid. When the solvent in question is water, such a solvate is usually called a hydrate.
[G87] The term agonist, as used in the context of the invention, refers to a substance (ligand) that activates the type of receptor in question.
[088] Throughout the description and claims, conventional one-letter and three-letter codes for natural amino acids are used, as well as three-letter codes generally accepted for other amino acids, such as sarcosine (Sar), norleucine (Nle) and aminoisebutyric acid (Aid). All amino acid residues in peptides of the invention preferably have the L configuration. However, the D-configuration amino acids can also be present.
[088] Among the sequences disclosed here are sequences that incorporate a Hy- ^:: chemical moiety at the amino (N-terminal) end of the sequence, and a chemical moiety or a -ΝΗ / no chemical moiety! (C · terminal) carboxy of the sequence. In such cases, and unless otherwise stated, a chemical portion ^! Ήγ- · ^Η in the N-terminus of the sequence in question indicates a hydrogen atom [for example, R '~ Hynas formulas I and Ia; corresponding to the presence of a free amino group
24/66 primary or secondary at the H-terminal], while a chemical "-OH or" -NH / at the C-terminal of the sequence indicates a hydroxy group [for example, A ² ~ OH in formulas I to Ia; corresponding to the presence of a C-terminal nu carboxy group (COOH)] or an amino group [for example, R ² ~ NH _; in formulas I and Ia; corresponding to the presence of a starch group (CONH _S ) in the Cterminal], respectively. In each sequence of the invention, a chemical moiety -0H the C-terminus may be substituted by a chemical ^{moiety! NHG,!} in the C-terminal, and vice versa.
[080] As used herein, a conservative ^-1 substitution means that an amino acid residue that belongs to a certain position in the peptide sequence of human native GLP-2 has been replaced by an amino acid residue that belongs to the same group (I , II, Ri, IV, V, 1, 2,3), as defined in the following table:
[081] A non-conservative substitution, as used herein, means any substitution other than a conservative substitution of an amino acid residue from the native GLP-2 sequence
26/66 for example, substituted by a non-natural non-protecting ammoacid (Sar. Nle <Aib) or substitution by an amino acid that does not belong to the same group.
[092] & n some embodiments of the invention, a compound. This invention has at least one activity. of LPG-S and GUM. 'Kemplfeiivas activities include reducing the permeability of the intestine to alter inflammation in the intestine. taco can be evaluated in tests in wo <for example described in <a> eumpump> in which the mass and penneability of the intestine, or a portion of it, is determined after an animal has been treated or exposed to a · GLP-2 analog.
[093] In some embodiments, nm GLP analogs% of the invention has at least 60% sequence identity to GLP-2 wild-type (V33) that has the ifie-Ale-Aspr-Gly-Ser-P sequence ^ -Be-v ^ sp-GiuMei.-AsB ^ hr-4ie ^^
Gln-Tbr-Lys ^ le-ThpAsp ·. · For example, a GLP'2 analogue of the invention can have about 60% sequence identity, for example, between
about 6% to 30% and, in changed canes _: £ islo minus 63%, 66% or 63% of string identity,fôá41 ^ Percentage (%) of identity supply of amino acids ⁰ inrelation to the sequelai and pm-peptides of QlP-2 s dsfi vdo as poroenlspem of the residues of amincàcidò in a sequence in the ; ndidata that is ídóshos to amiaoacid residues in the sequence of GLP-2 r I was going wild, after swimming
the sequences and introduce intervals, if neosssáho _: to reach the maximum percentage of the sequence identity, and without considering any oonwyaüvas substitutions as part of the sequence identity, the sequence alignment can be performed by a person skilled in the art with the use of ixsn techniques (>:> nhucidas na tênníí a .: exumpio, with the use of software publinarmmte dlswnívec such as software BLAST, BLASTS, nu Align, For example, consult Aitechui st al, Methods m Bnzymuwy 3 && 43Ô to 460 {tggs) . Pearson et aL Gsnomios-46: 94 to 36 .. WA and
26/66 alignment program on the molbio <soton website, ac.uk / compute / align, [Ô95] The percent sequence identities used here and in accordance with the present invention can be determined using these programs with their default settings. More generally, one skilled in the art can readily determine the appropriate parameters for determining alignment, including any algorithms necessary to achieve maximum alignment over the total length of the sequences being compared.
[698] In some embodiments, a GLP-2 analogue of the invention comprises more than one substitution (i.e., more than one substitution with respect to the wild type GLP-2 sequence given above) at positions X2 , X3, X5. X7, X8, X9, X10, X11, X12, XI3, X14, X15, X16, XI7, XI9, X20, X21, X24, X27, X28, X29, X30, X31, X32 and X33.
[697] In some embodiments of the invention, a GLP-2 analogue of the invention comprises more than one substitution (i.e., more than one substitution with respect to the wild type GLP-2 sequence given above) at positions X2, X3, X5, X7, X3, X9, X10, X11, X12, XI3, X15, X16, X17, X2D, X21, X24, X27. X28, X29, X30, X3U, X32 and X33.
[098] In some embodiments, amino acid residues at positions X28, X29, X30, X31, X32 and X33 are optionally reported.
[089] Without sticking to the theory, it is believed that a polar or charged residue (for example, Gin, Lys or Glu) in a position corresponding to position 17 of a peptide sequence of native GLP-2, rather than Leu found in the native GLP-2 peptide sequence, can interact with and activate the GLP-1 receptor. A polar or charged amino acid at position 17, then, can alter the selectivity of the GLP-2 peptide receptor or analogs thereof, resulting in double agonistic peptides that activate both GLP-1 and GLP-2 receptors.
[180] Without sticking to the theory, it is believed that a small amino acid residue (for example, Gly, Ser or Ala) at position 18 may be preferred
27/66 to introduce or improve the GLP-1 receptor activity of a GLP-2 peptide analogue. However, it may also be possible to obtain better GLP-1 receptor activity with other amino acid substitutions as long as the amino acid at position 17 is polar or charged.
[101] In some embodiments of the invention, a GLP-2 analogue, as described above, comprises a lipophilic substitute conjugated to one or more of positions 12, 14,16, 17,19, 20. 24, 27, 28 and 32.
[102] In some embodiments, a GLP-2 analogue, as described above, comprises a lipophilic substitute conjugated to one or more of the positions 12,16,17, 20, 24. 27, 28 and 32, [103 ] In a preferred embodiment of the present invention, the GLP-2 analogue, as described above, comprises a lipotyl substitute conjugated to one or more of positions 16,17, 20 and 24.
[104] Exemplary compounds of the invention (derived from Formula I, Formula ia to Formula II) are described below, wherein said compounds can be modified at the N-terminus at the C-terminus as described for R and R and including a pharmaceutically acceptable salt or derivative thereof: Hy-H-Aib-DGSFSDEMNTiLDNQAARDFINWUQTKITD-QH; (Compound 1) Hy-HGDGSPSDEMNTILDNKAARDFINWLiQTKITD-OH; (Compound 2) Hy-HGDGSFSDEMNTILDGQ, AARDFINWL1QTK-NH2: (Compound 3) Hy-HGDGSFSSEMNTILDSQAARDFINWLIQTKITD-OH; (Compound 4) Hy-HGEGTFTSDLSKQMEGQAVRDFiEWLIQTKITD-OH; (Compound 5) Hy-HGEGTFTSDLSKQMESKAARDFIEWLIQTKIDT-OH; (Compound 6) Hy-HGDGSFSSELATILDGKAARDFINWLIQTKITD-OH: (Compound 7) Hy-HGEGTFTSDLSTILENKAARDFIEWUQTKITD-OH; (Compound 8) Hy-HGEGSFSSDLSTILENKAARDFiEWUQTKÍTD-OH; (Compound 9) Hy-H ~ Aíb-DGâFSDELNTILDGKAARDFIMWLIQTK ~ NH2; (Compound 10) Hy-HGDGSFSGELATiLDGQAARDFIAWLIQTKITD-OH; (Compound 11) Hy-HGDGSFSDEMNTILDGQAARDFINWUQTK-NH2; (Compound 12) Hy-HGEGSFSSDLSTILEGKAAROFIEWLIQTKITD-OH: (Compound 13)
28/66 [105] In some embodiments, the present invention provides the use of GLP-2 analogs of the Invention for the preparation of a medicament for the treatment and / or prevention of Gastrointestinal Inflammation, for example, related low grade gastrointestinal inflammation to diabetes, [106] In some embodiments, the present invention provides a nucleic acid molecule that comprises a nucleic acid sequence that encodes a GLP-2 analog, as defined herein.
[107] In other respects, the present invention provides an expression vector comprising the above nucleic acid sequence, optionally in combination with sequences to direct its expression, and host cells transformed with the expression vectors. Preferably, host cells can express and secrete the GLP-2 analog. In a still further aspect, the present invention provides a method for producing the GLP-2 analog, the method comprising culturing the host cells under conditions suitable to express the GLP-2 analog and then purifying the GLP-2 analog. produced, [108] The Invention further provides a nucleic acid of the invention, an expression vector of the invention or a host cell that can express and secrete a GLP-2 analog of the invention, for use in therapy. It will be understood that the nucleic acid, expression vector and host cells can be used for the treatment of any of the disorders described here that can be treated with the GLP-2 analogs themselves. References to a therapeutic composition comprising a GLP-2 analog of the invention or the administration of a GLP-2 analogue of the invention should therefore be interpreted in a muted manner to encompass the administration of an nucleic acid, an expression vector or a host cell of the invention, except when the context indicates otherwise.
[109] In some embodiments, the present invention provides the use of a nucleic acid molecule, an expression vector or a host cell as defined herein, in the preparation of a medicament for the
29/66 treatment and / or prevention of gastrointestinal inflammation [110] In some embodiments, the present invention provides a method for treating low-grade gastrointestinal inflammation related to diabetes.
[111] In some embodiments, the present invention provides a method to treat or prevent low-grade gastrointestinal inflammation related to diabetes in a patient who needs it, the method comprising administering an effective amount of a nucleic acid, a vector expression cell or a host cell of the Invention.
[112] As described above, the GLP-2 analogs of the invention have one or more amino acid substitutions, deletions, inversions or additions when compared to native GLP-2. This definition also includes the synonymous terms MLM-GLP-2 and / or GLP-2 agonists. In addition, an analogue of the present invention may additionally have a chemical modification of one or more of its side amino acid groups, ocarbon atoms, terminal amino group or terminal carboxy acid group. A chemical modification includes, but is not limited to, adding chemical moieties, creating new bonds and removing chemical moieties. Modifications to amino acid side groups include, without limitation, the acylation of lysine s-amlno groups, the N-alkylation of argin, histidine or Plant, the alkylation of carbexyl, glutamic or aspartic groups and the deamidation of glutarnin or asparagine. Modifications of the N-terminal amino group include, without limitation, design changes, lower N-alkyl, lower N-lower alkyl and N-lower alkyl. Modifications of the C-terminal carboxy group include, without limitation, modifications of amide, lower alkylamide, diaiquyl and lower alkyl ester. Preferably, a lower alkyl is C _; -C.-alkyl. In addition, one or more functional groups in side chains whose terminal groups can be protected by protecting groups known to one skilled in the art. In some embodiments, the amino carbon of an amino acid can be mono- or di-methylated.
[113] When present, a Met substitution amino acid
Oxidatively stable 30/66 means that it is selected from the group consisting of Met (O) (methionine sulfoxide), Met (O) s (methionine sulfone), Vai, lie, Ser and, preferably, lie, Leu, Go, Lys or Ser.
[114] One or more of the amino acid side chains in a compound employed in the context of the invention can be conjugated to a lipophilic substituent Z Without adhering to the theory, it is believed that a lipophilic substituent binds to Albumin in the bloodstream, thereby protecting the compounds used in the context of the invention from enzymatic degradation, which can improve the half-life of the compounds. The lipophilic substituent can also modulate the potency of the compound, for example, with respect to the GLP-2 receptor and / or the GLP-1 receptor.
[115] In certain embodiments, a side chair of the amino acid is conjugated to a lipophilic substituent. In other embodiments, each of two side chains of the amino acid is conjugated to a lipophilic substituent. In additional embodiments, three or even more side chains of the amino acid are conjugated to a lipophilic substituent. When a compound contains two more lipophilic substitutes, they can be the same or different substitutes.
[116] The lipophilic substituent Z 'can be covalently attached to an atom in the side chair of the amino acid, or alternatively it can be attached to the side chair of the amino acid by one or more 2' spacers.
[117] The term conjugate is used here to describe the covalent bond of one identifiable chemical moiety to the other and the structural relationship between such chemical moieties. It could not be considered to imply any particular method of synthesis. The one or more spacers 22, when present, are used to provide spacing between the compound and the lipophilic chemical moiety.
[Í18] A lipophilic substituent could be attached to a side chair of the amino acid or to a spacer by means of an ester, a sulfomyl ester, a
Accordingly, it will be understood that a lipophilic substituent can include an acyl group, a sulfonyl group, an N atom, an O atom or an S atom that is part of the ester, sulfonyl ester, thioester , amide or sulfonarnide. Preferably, an acyl group in the lipophilic substituent is part of an amide or ester with the side chair of the amino acid or spacer. The lipophilic substituent may include a hydrocarbon chain having 10 to 24 carbon atoms (Cp for example. 10 to 22 atoms of C, for example, 10 to 20 atoms of C <Preferably, it has at least 11 atoms of C and, preferably, it has 18 atoms of C and minus. For example, the hydrocarbon chain may contain 12, 13, 14, 15, 16, 17 or 18 carbon atoms, The hydrocarbon chain can be straight or branched and can be saturated or unsaturated In the light of the above discussion, it will be understood that the hydrocarbon chain is preferably substituted by a chemical moiety that forms part of the link to the side chair of the amino acid or spacer, for example, an acyl group, a sulfonyl group, an N atom, an O atom or an S atom. Most preferably, the hydrocarbon chain is replaced by an acyl group and, consequently, the hydrocarbon chain can be part of an alkanoyl group, for example, a dodecanoia, 2'butyloctanoyl, tetradecanoyl, hexadecanuyl, heptadecanoyl, ootadecanoyl or eicosanoyl group.
[119] As mentioned above, the lipophilic substituent Z 'can be conjugated to the side chair of the amino acid by one or more aspirators Z ² , When present, the spacer is attached to the lipophilic substituent and the side chair of the amino acid. The spacer can be attached to the lipophilic substituent and the side chair of the amino acid independently by an ester, a sulfonyl ester, a thioester, an amide or a sulfonamide. Consequently, it may include two chemical moieties independently selected from acyl, sulfonyl, an N atom, an O atom or an S atom. The spacer may consist of one. linear hydrocarbon chain or, more preferably, a linear Cvx hydrocarbon chain In addition, the
32/66 spacer can be substituted by one or more substituents selected from 0Â ° alkyl, CW alkylamine, C1 alkylalkoxy and C1 alkylalkoxy.
[120] The spacer may, for example, be a residue of any naturally occurring or unnatural amino acid. For example, the spacer may be a residue from Gly, Pro, Ala, Vai, Leu, He, Met, Cys, Phe, Tyr, Trp, His, Lys, Arg, Gin, Asn, a-Glu, y-Glu, s-Lys, Asp. Ser, Thr, Gaba, Aib, β-Ala (i.e., 3-aminoprapanoyl), 4-amnobutanoyl, 5-aminopentanoyl, 8 aminohexanoyl. 7-aminoheptanoyl, 8-aminooctanoyl, 9-aminononanoyl, 10 aminodecanoyl or 8-amino-3,6-dioxantanano. In some modalities, the spacer is a residue of Glu, γ-Glu, ε-Lys, β-Ala (that is, 3-aminopropanoyl), 4-aminobutanoyl, B-aminooctanoyl or e-amino-Se-dioxaoctanoyl. In the present invention, y-Glu and isoGlu are used interchangeably. The side chair of the amino acid to which the lipophilic substituent is conjugated can be a side chain of a residue from Glu, Lys, Ser, Cys, Dbu, Dpr or Orn. For example, it can be a side chain from a Lys, Glu or Cys residue. When two or more side chains prune a lipophilic substituent, it can be independently selected from those residues. So, the amlnoacid side chair includes a carboxy group. hydroxy, thiol, amide nu amine, to form an ester, a suiphonyl ester, a thioester, a nu amide a sulfonamide with the lipophilic spacer or substituent, [121] As an example of a lipophilic substituent comprising a lipophilic chemical portion Z ¹ and spacer Z ~ is shown in the formula below:
33'68 „3 ..- 1 λ χ <ΗιΓ y ''> f 'V' ^x 'M'
MW j y λ: Γ V
Á Λ G <Jíl [122] Here, the side chain of a Lys residue is covatably linked to a y-GG spacer (Z ² ) by means of an amide bond. A hexadecanoyl group (Zl) is covalently linked to the y-Glu spacer by may an amide bond. This combination of lipophilic chemical portion and spacer, conjugated to a single Lys residue, can be called the abbreviated notation K (Hexadscanaíla-y-Gto), for example, when shown in specific compound formulas, y-Giu can also be called isoGlu , and a hexadecanoyl group as a pyramitoyl group. It will then be evident that the notation (Hexadecanoyla-y-Glu) is equivalent to the notations (ísoGlu (Palm)) or (iscGlu (Palmitoiia)) as used, for example, in document PGT / GB200B / 004121, [123] The person skilled in the art is aware of suitable techniques for preparing the compounds employed in the context of the invention. For examples of suitable chemistry, see WO98 / 08871, WOOO / 55184, WOOO / 55119, Madsen et al, J. Med. Chem. 50: 6126 to 6132 (2007), and Knudsen et al., J, Med Chem. 43: 1884 to 1669 (2000), hereby incorporated by reference.
[124] In some embodiments, a GLP2 analogue of the invention has an lipophilic substituent, as described above, conjugated to an amino acid in one or more of the positions corresponding to positions 12, 14,16,17,19, 20, 24, 27 , 2.8 and 32 of the native GLP-2.
34/66 [125] In some embodiments, a GLP2 analog of the Invention has a subtype Hpofilium, as described above, conjugated to an amino acid in one or more of the positions corresponding to positions 12, 16.17, 20, 24, 2'7, 28 and 32 of the native GLP-2.
[126] It should be understood that the peptides of the invention can also be in the form of one derivative or another. Salts Include pharmaceutically acceptable salts, such as acid addition salts and basic salts. Examples of acid addition salts include hydrochloride salts, citrate salts, lactate salts, malate salts and acetate salts. Examples of basic salts include salts in which the cation is selected from alkali metals, such as sodium and potassium, alkaline earth metals, such as calcium, and ammonium ions WR (afFT), where R ³ and R ⁴ designate independently optionally substituted C _2, and alkyl, optionally substituted C 4, alkenes, optionally substituted aryl or optionally substituted heteroaryl. Other examples of acceptable farmaceutlcamente salts are described in "Remington's Pharmaceutical Sciences, 17th Edition, Ed. Alfonso R Gennaro (Ed.), Mark Publishing Company, Easton, PA, USA, 1985 and more recent editions, and in Encyclopedia Pharmaceutical Technology (Enoiefopaedía of Pharmaceutical Technology), [127] Other derivatives of the GLP-2 analogs of the invention include coordination complexes with metal ions, such as Mn ² 'and Zn ² esters, such as hydrolyzable esters. wvo, free acids or bases., hydrates, prodrugs or ilpids. Esters can be formed between hydroxyl groups or carboxylic acid present in the compound and a reaction partner of suitable acid or alcohol, using techniques well known in the art. Derivatives that are prodrugs of the compounds are convertible into or out of one of the parent compounds. Typically, at least one of the biological activities of the compound will be reduced in the prodrug form of the compound, and can be activated by converting the prodrug to release the compound or a metabolite thereof. Pro-drug examples include and
35/66 use of protective groups that can be removed fo, releasing the active compound, or work to inhibit the clearance of the drug wVc.
[120] GLP-2 analogs that have an EC50 value of 1 nM or less, and preferably below 1 nM, are defined as GLP-2 agonists.
[129] The present invention includes the following peptides described further in the experiments below.
Synthesis of GLP-2 analogs [130] It is preferable to synthesize the analogs of the invention by means of peptide synthesis in solid or liquid phase. In this context, the skilled in the art can see PCT publication WO 98 / 111.25 a Fields, GB et al, 2002, Principles and practice of solid-phase peptide synthesis on: Synthetic Peptides (2nd Edition) (herein incorporated titer reference ) and the Examples of the preseme documents.
[131] So, GLP-2 analogs can be synthesized in several ways, including, for example, a method that comprises:
(a) synthesizing the peptide by peptide synthesis in solid or liquid phase and recovering the synthetic peptide then obtained;
(b) when the peptide consists of naturally occurring amino acids, express a nucleic acid construct that encodes the peptide in a host cell to recover the expression product from the host cell cut:
(when the peptide consists of naturally occurring amino acids to carry out cell free expression of a nucleic acid construct that encodes the peptide and recover the expression product; or a combination of methods of (a), (b) and (c ) to obtain fragments of the peptide, subsequently join (for example, ligate) the fragments to obtain the peptide and recover the peptide.
[132] Thus, for some analogs of the invention, it may be advantageous to explore genetic engineering techniques. This may be the case when the
36/66 peptide is large enough (or produced as a fusion construct) and when the peptide includes only naturally occurring amino acids that can be translated from RNA into living organisms.
[133] For the purposes of recombinant gene technology, the nucleic acid fragments encoding the peptides of the invention are important chemicals. Therefore, an additional aspect of the present invention provides a nucleic acid molecule comprising a nucleic acid sequence that encodes a GL.P-2 analog of the invention, where the peptide is preferably composed of naturally occurring amino acids. The nucleic acid fragments of the invention can be fragments of DMA or RMA.
[134] The nucleic acid fragments of the invention will normally be inserted into suitable vectors to form expression or cloning vectors that carry the nucleic acid fragments of the invention. Such new vectors are also part of the invention. The details regarding the construction of these vectors of the invention will be discussed in the context of transformed cells and microorganisms. The vectors can be, depending on the purpose and the type of application, in the form of plasmids, phages, oosmids, minloromassomes or viruses, however, the naked DNA that is only transiently expressed in certain cells is also an important vector. The preferred cloning expression vectors (plasmid vectors) of the invention are capable of autonomous replication, thereby allowing high copy numbers for the purposes of high-level expression or high-level replication for subsequent cloning.
[135] The general profile of a vector of the invention comprises the following characteristics in the 5 'to 3 * direction and in operable link: a promoter to activate the expression of the nucleic acid fragment of the invention, optionally, a nucleic acid sequence that encodes a leader peptide that allows secretion (for the extracellular phase or, when applicable, in the peripiasm) or a leader peptide for multiple uses, for example, combined secretion,
37/66 enzymatic purification and trimming tag to correct the peptide or membrane integration of the polypeptide fragment, the nucleic acid fragment encoding the peptide of the invention and optionally a nucleic acid sequence encoding a terminator. In order to operate one hundred expression vectors in cell lines or producing strains, it is preferred, for the purposes of genetic stability of the transformed cell, that the vector, when introduced into a host cell, be integrated into the genome of the host cell.
[138] The vectors of the invention can be used to transform host cells to produce a GLP-2 analog of the invention. Such transformed cells, which are also part of the Invention, can be cells or cultured cell lines used for the propagation of the nucleic acid fragments and vectors of the Invention, or used for rewiring the peptides of the invention.
[137] The preferred transformed cells of the invention are microorganisms, such as bacteria, including, for example, bacteria of the genus Escherichia (for example, E. coli), Bacillus (for example. Bacillus subtilis), Salmonella or Mycobacterium (preferably, non-pathogenic, for example, M. bovis BCG)), yeasts (such as Saccharomyces cerevisiae) and protozoa. Alternatively, the transformed cells can be derived from a multicellular organism, for example, fungal cells, insect cells, plant cells or mammalian cells (for example, cells derived from a human), For the purposes of cloning and / or improved expression, it is preferred that the transformed cell can replicate a nucleic acid fragment of the invention. Cells expressing a nucleic fragment of the invention are preferred useful embodiments of the invention. These can be used for small-scale or large-scale preparation of the peptides of the invention.
[138] When producing a peptide of the invention by means of transformed cells, it is convenient, although not essential, that cells
38/66 export the expression product to the culture medium or carry the expression product on the transformed cell surface.
[139] When an effective producer cell is identified, it is preferable, based on it, to establish a stable cell line that carries the vector of the invention and expresses the nucleic acid fragment encoding the peptide. Preferably, this stable cell line secretes or carries the peptide of the invention, thereby facilitating its purification, [140] In general, plasmid vectors containing replicon and control sequences, which are derived from compatible species with the host cell, they are used in conjunction with a host. The vector normally has a replication site, well conic marker sequences, which can provide phenotypic selection in transformed cells. For example, E. coli can typically be transformed using pBR322 (although several other useful piasmids exist), a plasmid derived from an E. coli species (see, for example, Bolívar et al., 1977). Plasmid p8R322 contains genes for ampicillin and tetracycline resistance and then provides easy means for identifying transformed cells. The pBR plasmid, or other microbial phage or plasmid, must also contain or be modified in the mute that contains promoters, which can be used by the prokaryotic microorganism for expression, [141] Those promoters most commonly used in the construction of recombinant DMA prokaryotic include the beta-lactamase (pemcllinase) and lactose (Chang et al., 1978; Itakura et at, 1977: Goeddel et al. 1979) promoter systems and a tryptophan (trp) promoter system (Goeddel et al-, 1979 ; EP 0 036 776 A), Although these are most commonly used, other microbial promoters have been discovered and used, and details regarding their nuclaotide sequences have been published, allowing one skilled in the art to link them in a functional way with plasmid vectors (Siebweníist. Et al „1980).
39/68 [142] In addition to prokaryotic microbes, eukaryotic microbes, such as yeast cultures, can also be used. In these modalities, a promoter must also have the ability to activate expression. Saccharomyoes cerevisiae, or common baker's yeast, is the most commonly used among euoarytoid microorganisms, although several other strains are commonly available. For example, Píchia stiptis and Schizosaochammyces dove can also be used. For expression in Saooharomyces, the plasmid ¥ Rp7 <for example, is commonly used (Stinchcomb et al, 1979; Klngsman et al, 1979; Tschemper et al _.; 1980). This plasmid already contains the trpl gene that provides a selection marker for a mutant strain of yeast that lacks the ability to grow into tryptophan (for example, ATCC · n ^and 44076 or PEP4-1) (Jones, 1977). The presence of the trpl lesion as a characteristic of the yeast host cell genome then provides an effective environment for detecting transformation by development in the absence of tryptophan.
[143] Suitable promoter sequences in yeast vectors include promoters for 3-phosphoglyceratu kinase (Hitzman et al ,, 1980) or other glycolytic enzymes (Hess et al, 1968; Holland et al., 1978), such as enolase, glyceraldehyde-3®sulfate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphoturethokinase, glucose-8-phosphate isomerase, 3phostoglycerate mutase, pyruvate kinase, triosphosphate isomerase, phosphoglucose isomerase and gluookinase. In constructing suitable expression plasmids, the termination sequences associated with these genes are also linked to the 3 'expression vector of the sequence to be expressed in order to provide polyadenylation of the mRNA and termination.
[144] Other promoters, which have the added advantage of transcription controlled by developmental conditions, are represented by the promoter region for alcohol dehydrogenase 2 _S isocytochrome C, acid phosphatase, degradative enzymes associated with hydrogen metabolism, and glyceraldehyde3 ~ fcsf ' dehydrogenase act mentioned earlier, and enzymes
40/66 responsible for the use of maltose and galactose. Any plasmid vector that contains a yeast compatible promoter, origin of replication and termination sequences is suitable.
[145] In addition to mloro-orgaBsmcs, cell cultures derived from multicellular organisms can also be used as hosts. In principle, any cell culture is usable, whether from vertebrate or invertebrate culture, however, the greatest interest has fallen on vertebrate cells, and the propagation of vertebrates in culture (tissue culture) has become a routine procedure in recent years (Tissue Culture, 1973). Examples of such useful host cell lines are VERO and Heha cells, Chinese hamster ovary (CHO) cell lines and W138, BHK, QOS-7293 cells. Spodoptera fruglperda (SF) cells (commercially available as complete expression systems with, among others, Protein Sciences, 1000 Research Parkway, 'Meriden, CT 08430, U.S.A, and with invitmgen), the D. melanogaster S available from Invitrogen, PO Bex 2312, 9704 CH Groningen, The Netherlands, and MOCK cell lines.
[145] Expression vectors for such cells usually include (if necessary) a replication origin, a promoter located in front of the gene to be expressed, along with any necessary ribosomal binding sites, RNA splice sites, polyadenylation and transitional transitions.
[147] For use in mammalian cells, the control functions in expression vectors are often provided via viral material. For example, the promoters commonly used are derived from poiloma, Adenovirus 2 and, more often, Simian Virus 49 (SV40). The early to late promoters of the SV4D virus are particularly useful because both are easily obtained from the virus as a fragment, which also contains the SV40 viral origin of replication (Piers et al „1978). Smaller or larger SV40 fragments can also be used, provided
41/66 that the sequence of approximately 250 bp is included that extends from the Hindi site !! towards the Bgli site located at the origin turns! replication. In addition, it is also possible, and often desirable, to use control or promoter sequences normally associated with the desired genetic sequence, provided that such control sequences are compatible with the host cell systems.
[148] An origin of replication can be provided by constructing the vector so that it includes an exogenous source, as well as it can be derived from SV40 or another virus (for example, Potioma, Adenovirus, VSV and BPV). or it can be provided by the host cell's chromosomal replication mechanism. If the vector is integrated into the host cell's chromosome, it is often sufficient.
[149] In order to obtain satisfactory yields in a recombinant production process, it may be advantageous to prepare the analogs as fusion proteins, by fusing the peptide to a fusion partner that can function as a affinity (for ease of purification) and / or obtaining multiple replicates of the peptide. These methods require the presence of a suitable dividing site for a peptidase. The person skilled in the art will know how to adapt the underlying genetic constructs.
[159] After recombinant preparation, the peptides of the invention can be purified by methods generally known in the art, including multistep oromatoography (for example, chromatographic techniques of tonic exchange, exclusion by size and affinity).
[1S1] Alternatively, peptides composed of naturally occurring amino acids can be prepared m v / fro in cell-free systems. This is especially convenient in cases where the peptides could be toxic to putative host cells. Therefore, the present invention also contemplates the use of cell-free translation / expression in order to prepare the peptides of the invention. In this context, reference is made to kits, materials and technical documentation of translation to v / fro commercially available from <per exempts, Arabian tem, 213Ç Woodward, Austin, TX 78744-1832, USA ..
(152} Finally, it is clear that the methods available can be combined to prepare, for example, healthy analogues. In such a configuration, the fragments of peptic to the prepared prepared use at least 3 steps or separate methods, succeeded by the union (e.g., ligation) of the fragments to generate the peptide end product.
(153 | Typically, the GLP-3 antibodies of the invention have activity at both GLP-i and GLP-S receptors.
(154] The EOso values can be used as a numerical measure of the potency of agonists at a given receptor.A EC value is a measure of the strength of a compound required to achieve half of the activity: of that compound in a particular assay A compound that has an EG3 in a particular receptor that is internal to the EO3 and a reference compound in the same assay can be identified as having a greater potency in that receptor than the retention compound.
(155] The GLP-2 antibodies of the invention typically have a greater effect on the OLFM receptor (e.g. the human GLP-1 receptor) than the human wild-type GLPd (hGLP-2). So, in any assay given for the GtF-1 activity, the GLP ^ 2 air will be an ECu menor smaller than the human GliP-S of the dpo sohmgem uu [Giy2] -hGLP-2 (ie, GLP * 2 human that has glycemia in position 2, also not rated as tedugíutldah Guando evaluated in the same activity range of GIPM> the ratio between the 6¾ of the GLP-G analog and the EC ^ of nGLP-2 or {Giy2] -hGLP-2 This modm is typically less than ai, It may be, for example, less than 0Λ inside me OJ <to içtsdár to 0.Ό1.
(155] 0 ECXí> in the pruning GLP-1 receptor, be less than 1ü0 nPt less than
SO nM, inside 10 nM or, more preferably, lower than AO nM, less than CG uM. _: less than 0 _: β nM, inside 0.7 nM, less than 0.8 nM _s less than 0.5 nM, less than 0 <4 nM _: less than 0.3 nM. less than M nM _; - less than 03 · πΜ, less than
43/66
0.09 nM, less than 0.08 nM, less than 0.07 nM. less than 0.06 nM, less than 0.05 nM, less than 0.04 nM, less than 0.03 nM, less than 0.02 nM, less than 0.01 nM, less than 0.009 nM, less than 0.008 nM, less than 0.007 nM, less than 0.006 nM, or less than 0.005 nM, for example, when evaluated using the GLP-1 receptor efficacy assay described in Example 1.
[167] The GLP-2 analogs of the invention retain GLP-2 activity, although their potency at the GLP-2 receptor need not be the same as that of hGLP-2 or [Gly2] -hGLP-2 They may have a lower potency since adequate levels of GLP-2 activity are retained. In any assay given for GLP-2 activity, GLP-2 analogs can have an EC ^ Lower or greater than human GLP-2 of the wild type or [Gly2] ~ hGLP ~ 2. When evaluated in the same GLP-2 activity assay, the ratio between the ECso of the GLP-2 analog and the EC _gi3 of hGLP-2 or [Gly2] -hGLP-2 in the same assay can be, for example, less than 200, lower 100, lower 10, lower 5, lower 1, lower 0.1, lower 0.5 or lower 0.1 [158] It may also be desirable to compare the ratio of EC values _S0 at the GLP-1 receptors and of GLP-2 for the analogue of the invention and for hGLP-2 or [Gly2] -hGLP-2, Preferably for a given pair of GLP-2 and GLP-1 assays. the analogue of the invention has an ECsdGLP2] / ECso [GLP-1] which is higher than the equivalent ratio for hGLP-2 or [Gly2] ~ hGLP-2 in the same assays, for example, the ratio of the analogue of the invention can be at least 2, at least 5 or at least 10 times greater than that for hGLP-2 or [Gly2] -hGLP-2 <
Pharmaceutical Compositions and Administration [159] The GLP-2 analogs of the present invention, or salts or derivatives thereof, can be formulated as pharmaceutical compositions prepared for storage or administration, and which comprise a therapeutically effective amount of a GLP-2 peptide of the present invention, or a salt or derivative thereof, in a pharmaceutically acceptable carrier.
44/66 [160] The therapeutically effective amount of a compound of the present invention will depend on the route of administration, the type of mammal being treated and the physical characteristics of the specific mammal under consideration. These factors and their relationship with the determination of this quantity are well known to those skilled in medical techniques. This amount and the method of administration can be adjusted to achieve ideal efficacy in order to distribute the peptides in the large intestine, however, it will depend on such factors as weight, diet, concomitant medication and other factors, well known to those skilled in the art. medical.
[161] It is an object of the invention to provide a pharmaceutical composition, in which a GLP-2 analogue of the invention, or a salt thereof, is present in an amount effective to treat or prevent disorders related to the stomach and intestine.
[162] Pharmaceutically acceptable salts of the compounds of the Invention that have an acidic chemical moiety can be formed using organic and inorganic bases. Suitable salts formed with bases include metal salts, such as alkali metal or alkaline earth metal salts, for example, sodium, poiasium or magnesium salts; ammonium salts and organic amine salts, take as those formed with morpholine, tlomorpholine, piperidine, pyrrohydine, a mono-, di- or trl- lower alchamine (eg, etll-tercbutll-, diet'll ·, dilsopropyl-, trietii, tributyl-dimethylprapylamine), or a mono-, di- or trihydroxy lower alkylamine (for example, mono-, dl · · or triethanolamine). Internal salts can also be formed. Similarly, when a compound of the present invention contains a basic chemical moiety, salts can be formed using inorganic organic acids. For example, salts can be formed from the following acids: acetyl, propionic. lactic, citric, tartaric, succinic, fumaric, maieic, mayonian, mandelic, malt, italic, hydrochloric, hydromobromic. phosphorous, nitric, sulfuric, methanesulfonic, naphthalenesulfonic, beozenesulfonic, toluenesulfonic and camphor sulfonic, as well as other pharmaceutically acceptable acids
46/66 known. Amino acid addition salts can also be used formed with amino acids, such as lysine, glycine and fanylalanine.
[163] As it is clear to a person skilled in the art, a therapeutically effective amount of the peptides or pharmaceutical compositions of the present invention will vary depending on the age, weight of the species of mammal treated, the particular compounds employed, the particular mode of administration and desired effects and therapeutic indication. Due to the fact that these factors and their relationship with the determination of this amount are well known, the determination of therapeutically effective dosage levels, the amount necessary to achieve the desired result of preventing and / or treating diseases related to the intestine and stomach described here, as well as other medical indications revealed here, will be covered by the skills of the knowledgeable person.
[164] As used herein, ^<s a therapeutically effective amount is one which reduces symptoms of an given condition or pathology. preferably, that normalizes physiological responses in an individual with the condition or condition. The reduction of symptoms or the normalization of physiological responses can be determined with the use of a routine of methods in the technique and can vary with a particular condition or pathology. In one aspect, a therapeutically effective amount of one or more GLP-2 analogs of the Invention or one. pharmaceutical composition comprising one or more GLP-2 analogs of the invention is an amount that retrieves a measurable physiological parameter to substantially the same value (preferably up to 30%, more preferably up to 20% and even more preferably, up to 10% of the value) of the parameter in an individual without the condition or pathology.
[165] In one embodiment of the invention, administration of the compounds or pharmaceutical composition of the present invention is indicated at lower dosage levels, with dosage levels being increased until the desired effect of originating / treating the relevant medical indication, such as
46/66 diseases related to the intestine and stomach, be achieved. This can define a therapeutically effective amount. For the peptides of the present invention, alone or as part of a pharmaceutical composition, such doses can be between about 0.01 mg / kg and 100 mg / kg of body weight, such as between about 0.01 mg / kg and 10 mg / kg of body weight, for example, between 10 to 100 micrograms / kg of body weight.
[166] For therapeutic use, a GLP-2 analogue of the invention can be formulated with a canner that is pharmaceutically acceptable and is suitable for delivering the peptide by the chosen route of administration. For the purpose of the present invention, peripheral parenteral routes include intravenous, intramuscular, subcutaneous and intraperitoneal routes of administration. Certain compounds used in the present invention may also be susceptible to administration by the oral, rat, nasal, lower respiratory routes. These are called non-parenteral pathways. The present pharmaceutical composition comprises a GLP-2 analogue of the invention, or a salt or derivative thereof, and a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers are those used conventionally with peptide-based drugs, such as diluents, excipients and the like. Pharmaceutically acceptable dealers for therapeutic use are well known in the pharmaceutical art and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Go. (AR edition. Gennaro, 1985). For example, a saline solution to a phosphate buffered saline solution at either acidic or physiological pH can be used. Suitable pH buffering agents may be phosphate, citrate, acetate, tns / hydroxylmethyl) aminomethane (TRIS), NTns (hydroxymethyl) methyl * 3-aminopropanesulfonic acid (TAPS), ammonium bicarbonate, diethanolamine, histidine, which is a preferred buffer argin, lysine or acetate or mixtures thereof. Preferred buffer ranges are, in certain embodiments, pH 4 to 8, pH 6.5 to 8 e. more preferably, pH 7 to 7.5. Preservatives, such as para, meta and ortho-cresol, methyl and
47/66 propylparaben, fend, benzyl alcohol, sodium benzoate, benzoic acid, benzibbenzoate. sorbic acid, propanoic acid, hydroxybenzoic acid esters, can be supplied in the pharmaceutical composition. Stabilizers that prevent oxidation, deamidation, isomenization, racemization, cyclization, peptide hydrolysis, such as, for example, ascorbic acid, methionine, tryptophan, EDTA, asparagine, Plant, arginine, glutamine and glycine, can be provided in the pharmaceutical composition. Stabilizers that prevent aggregation, fibrillation and precipitation, such as sodium dodecyl sulfate, polyethylene glycol, carboxymethyl cellulose, cycludexin, can also be provided in the pharmaceutical composition. Organic modifiers for soiling or inhibiting aggregation, such as ethanoyl, acetic acid or acetate and salts thereof, can be supplied in the pharmaceutical composition. Isotonicity producers, such as salts, for example, sodium chloride or, more preferred carbohydrates, for example, dextrose, mannitol, lactose, irealose, sucrose or mixtures thereof, can be supplied in the pharmaceutical composition.
[167] Detergents, such as Tween 20, Tween 80, SDS., Pooxamers, for example, Pluronic F-88, Piuronic FM 27, can be provided in a pharmaceutical composition of the invention. Dyes and flavoring agents can also be provided in the pharmaceutical composition. In another embodiment, a pharmaceutically acceptable acid addition salt of a GLP-2 analogue of the invention is provided. Suspending agents can also be used.
[168] Organic modifiers, such as ethanoyl, tertiary-butanol 2propanol, ethanoyl, glycerol and polyethylene glycol, can be supplied in a pharmaceutical formulation for freeze-drying a Hofilized product. Bulking agents and isotonicity producers, such as salt, for example, sodium chloride, carbohydrates. eg dextrose, mannitol, lactose, trehalose, sucrose or mixtures thereof, amino acids (eg glycine and glutamate), or excipients, such as serum cysteine, lecithin or Albumins
48/66 human, or mixtures thereof. can be supplied in the pharmaceutical composition for lyophilization.
[169] The pharmaceutical compositions of the present invention can be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rat administration; preferably, sterile solutions or sterile powders or suspensions for administration for injection; and the like, The dose and method of administration can be adjusted to achieve optimal efficacy, however, this will depend on factors such as weight, diet, concomitant medication, which are recognizable by those skilled in the art.
[179] When administration is parenteral, such as intravenous and subcutaneous administration, injectable pharmaceutical compositions can be prepared in conventional ways, such as aqueous solutions or suspensions; solid iofilized forms suitable for reconstitution Immediately prior to use i suspension in liquid before injection, or as emulsions.
[171] Diluents for reconstituting the lyophilized product can, for example, be chosen from buffers listed above or selected from water, saline, dextrose, mannitol, lactose, treamosis, saoarose, lecithin, Albumin, giutamate of sodium, cysteine hydrochloride or water for injection with the addition or detergents, such as Tween 20, Tween 8Q, poloxamers (for example, Pluronic F-68 or Pluronic F-127), polyethylene glycol. and / or with the addition of preservatives, such as para-, meta- and ortho-cresol methyl, propylparaben, tenoi. benzyl alcohol, sodium benzoate, benzoic acid, benzii-benzoate, sorbic acid, propanoic acid, phydroxybenzicic acid esters, and / or with the addition of an organic modifier, such as ethancl, acetic acid, citric acid, lactic acid or salts of them.
[172] In addition, if desired, injectable pharmaceutical compositions may contain minor amounts of non-toxic auxiliary substances, such as wetting agents, or pH buffering agents. Absorption enhancement preparations (for example, liposomes, detergents and organic acids) can also be used.
[173] In one embodiment of the invention, the compounds are formulated for administration by infusion, for example, when used as liquid nutritional supplements for patients undergoing total parenteral nutrition therapy (for example, neonates, or patients suffering from caquexla) or anorexia), or by injection, for example, subcutaneously, intraperitoneally or intravenously, and are consequently used as aqueous solutions in sterile pyrogen-free form and optionally buffers at a physiologically tolerable pH, for example, a slightly acidic or physiological pH. The formulation for Intramuscular administration could be based on solutions or suspensions in vegetable oil for example, cinnamon oil, corn oil or soy oil. These oil-based formulations can be stabilized by antioxidants, for example, BHA (butylated hydroxyloisol) and BHT (butylated hydroxytoluene).
[174] Then, the GLP-2 analogs of the invention can be administered in a vehicle, such as distilled water or saline, phosphate buffered saline, sodium hydroxide solutions. 5% dextrose or oils. The sclubility of a GLP-2 analogue of the invention can be intensified, if desired, by incorporating a solubility enhancer, such as a detergent and / or emulsifier.
[176] The carrier or aqueous vehicle can be supplemented for injectable use with an amount of gelatin that works to deposit the GLP-2 analogue at or near the Injection site in order to provide a slow release at the site of action wanted. Alternative gelling agents, such as hyaluronic acid, can also be useful as depositing agents.
[176] The peptide compounds of the present invention can be used alone or in combination with compounds that have an anti-inflammatory effect. Without adhering to the theory, such treatment by combination can reinforce the beneficial treatment effects of the peptide analogs of the invention.
[177] The most appropriate dosage or therapeutic regimen for the
The treatment of a patient will, of course, vary according to the disease or condition being treated and according to the patient's weight and other parameters. Without sticking to any particular theory, it is expected that doses, in the microgram / kg or mg / kg range, and a shorter or longer frequency or duration of treatment can produce therapeutically useful results, such as a statistically significant increase, particularly in the small intestine mass. In some cases, the therapeutic regimen calls for the administration of appropriate maintenance doses to prevent tissue regression that occurs after discontinuing initial treatment. The most appropriate dosage sizes and dosing regimen for human use can be guided by the results obtained by the present invention, and can be confirmed in suitably designated clinical experiments.
[178] An effective dosage and treatment protocol can be determined by conventional means, by mingling with a low dose in laboratory animals and then increasing the dosage while the effects are monitored, and also by systematically varying the dosing regimen. The various factors can be considered by a doctor when determining an ideal dosage for a particular individual. Such considerations are known to the person skilled in the art.
[178] A human dose of a GLP-2 peptide according to the invention can, in an embodiment, range from about 10 micrograms / kg body weight / day to about 10 mg / kg / day, preferably , from about 50 micrograms / kg / day to about 5 mg / kg / day and, most preferably, about 100 micrograms / kg / day at 1 mg / kg, Mia.
Medical Affections [180] The o and GLP-2 analogs of the present invention are useful as one. pharmaceutical agent to prevent or treat an individual suffering from low-grade inflammation, for example, low-grade local or systemic inflammation. Low-grade inflammation can include, but is not limited to: metabolic syndrome, obesity (eg abdominal obesity),
51/66 diabetes, heart disease, gastrointestinal inflammation · depression, Alzheimer's, arthritis, hypertension, dyslipidemia and stroke, Gastrointestinal disorders, which include disorders of the upper gastrointestinal tract of the esophagus, can be treated by administering an effective amount of a GLP-2 analogue of the invention, or one thereof, as described herein. Disorders related to the stomach and intestine include ulcers of any etiology (for example, peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, infection-related ulcers or other pathogens), digestive disorders, malabsorption syndromes, short bowel, cul-de-sac syndrome, inflammatory bowel disease (Crohn's disease and uicerative colitis), celiac sprue (for example, due to gluten-induced snteropathy or celiac disease), tropic sprue, hypogammaglebulinemic sprue and mucositis and diarrhea induced by chemotherapy and / or radiation-hemotherapy.
[151] For patients who have a mucosal neoplasm of the gastrointestinal tract or an increased risk of mucosal neoplasia of the gastrointestinal tract, it may be desirable to select a dumb compound to reduce or cancel the risk of reduced side effects, such as stimulating or worsening mucosal neoplasia of the gastrointestinal tract · [152] Particular conditions that can be treated with a GLP-2 analog of the invention include the various forms of sprue, including heart sprue, which results from a toxic reaction to aifa-giiadin from heat s be a result of gluten-induced enteropathy or celiac disease, and is marked by a significant loss of small intestine villages; sprue from the tropics that results from infection and is marked by a partial flattening of the villi; sprue hlpogamagiobulinemicu which is commonly observed in patients with common variable immunodeficiency or hypogammaglabulinemia and is marked by a significant decrease in villus weight. , through evaluation
52/66 nutrient absorption biochemistry, through non-invasive determination of intestinal permeability through the patient's weight gain or through the improvement of symptoms associated with these disorders.
[183] The GLP-2 analogs of the present invention may be useful as pharmaceutical agents to prevent or treat disorders related to the stomach, including ulcers of any etiology (for example, peptic ulcers, Zoitinger-Ellison syndrome, drug-induced ulcers, ulcers related to infections or other pathogens).
[184] Other conditions that can be treated with the GLP-2 analogs of the invention, or for which the GLP-2 analogs may be useful prophylactically, include, in addition to the radiation entente mentioned above, an infectious or post-infectious entente. and damage to the small intestine due to toxic or chemotherapeutic agents for cancer.
[185] GL.P-2 analogs can also be used for the treatment of malnutrition, for example, cachexia and anorexia.
[188] A particular embodiment of the invention relates to the use of the present peptides for the prevention and / or treatment of intestinal damage or dysfunction The stem cells of the small intestine mucosa are particularly susceptible to the cytotoxic effects of chemotherapy due to their rapid proliferation rate (Keefe et al ,, Gut 2000; 47: 632 to 637). Administration of the present GL.P-2 peptide agonists can improve the trafficking effect in intestinal crypts and rapidly provide new cells to replace the damaged intestinal epithelium after chemotherapy and / or radiation therapy. An objective to be achieved by administering the GLP-2 analogs of the invention is to reduce the morbidity related to gastrointestinal damage in patients undergoing chemotherapy treatment while increasing tolerance to more aggressive chemotherapy, radiation and combination of chemotherapy and radiation therapies . Concomitant therapeutic or prophylactic treatment can be provided in accordance with the present invention to patients undergoing or about to undergo radiation therapy.
Densified that (i'87 | GasPelntestímu mucositis after chemotherapy to an erectile pemma which is an intractable essence, a voice that is established _: although it decreases gradually, Sunithe studies with the cystostatic drugs for cancer commonly used S-Ri are tenacious chemotherapy tenoses tenesno chemica with dredgers it assists pmduminantemrmte the function and the structural tetegrtea of the intsstkno slender, while s udten to the menus sesive and responds practically to an increased mucus (Gibwn st al., J Qástmenterdí HnpateL 18 (9;
1100v S003; Tamaki at al., Int Mad Res. 31 (1 to 18,2003}.
OPPdV-mediated actions (dipap ^ difpeptldasadV) adm-teísírando ^ is the patient who is aware of the same quantity of a GLP'2 analogue _: or one of the same. Such diseases include afflictions in which the enzyme
C & 5 a
In another embodiment, the invention describes a method for treating n
[182] The pharmaceutical composition. I could, in one embodiment, be thermedeed to cause the slow rise of a similar LPG-like dictation of a gu-derived salt, or even as above.
[150] It is contemplated that the present paptids may be used in a ministry to have neunams adn Inistreçde - 'If an effective quantity of an analogue gives LPG * 2. then one leaves the mesrnd. of the prevention, Cempiicaçdes with the food of the naïves due to the favela of development of the intestine can be surpassed with the users of the pspfidee of the invention, [151] In external wires, the invention ctescmve a method to treat attentions mediated by DPP-íV ( dipeptkiiipeptteasedVj admimstrandmse to a patient who does not even give an ethical amount of an artetege, or a salt thereof _: of the invention Such diseases include attacks on the OPPuV enzyme is overexpressed.
^ xampjp ^ [182] The following dxemptes are provided in order to illustrate preferred aspects of the invention and are intended to limit the scope of the invention.
oe GL
54/66
General Peptide Synthesis
Aparefoo and esírafég / a sfofof / ca [193] The peptides were synthesized in batches in a polyethylene tank equipped with a polypropylene filter for filtration using 9fluorenylmethyloxycarbonyl (Fmoc) with the Na-amino protecting group and common protective groups suitable for side chain features.
[194] The solid phase peptide synthesis was performed in a Peptidea Liberty Synthesizer available from CEM using the standard Frnoc chemistry. The TentaGei S Ram resin (1 g; 9.25 mmol / g) was swollen in NMP (10 ml) before use and transferred between the tube and the reaction vessel using DCM and NMP.
Accp / amento [195] A Fmoc-amino acid in NMP / DMF / DCM (1: 1: 1; 0.2 M: 5 ml) was added to the resin in a Discover microwave unit, available from CEM, with a HATU / NMP (0.5 M; 2 ml) and DIPEA / NMP (2.0 M; 1 mi), The coupling mixture was heated to 75 ° C for 5 minutes while nitrogen was bubbled through the mixture, The resin it was then washed with NMP (4 x 10 ml).
[196] In an alternative fashion, a Fmoc-amino acid in DMF / DCM (2: 1; 0.2 M; 5 ml) was added to the resin in a Discover microwave unit, available from CEM, from COMU / DMF ( 0.5 M; 2 ml) and DIPEA / DMF (2.0 M; 1 ml). The coupling mixture was heated to 75® for 5 minutes while nitrogen was bubbled through the mixture. The resin was then washed with NMP (4 x 10 ml),
Deprotection [197] Piperidine / NMP (20%: 10 ml) was added to the resin for initial deprotection and the mixture was heated by microwave (30 seconds; 40 '~ C). The reaction vessel was drained and a second portion of piperidine / NMP (20® 10 ml) was added and heated (75 ° C; 3 minutes) again. The resin was then washed with NMP (6 x 10 ml).
55/66 [193] Alternatively, piperidine / DMF (20%; 10 ml) was added to the resin for immortal deprotection and the mixture was heated by microwave (30 seconds: 40 ^W C). The reaction vessel was drained and a second portion of piperidine / OMF (20%; 10 ml) was added and heated (75 ° C; 3 minutes) again. The resin was then washed with DMF (8x10 ml), Acz / cadet action / stars / fopc / ona / J [199] Fmoc-Lys (ivDde) -OH or, alternatively, another amino acid with an orthogonal side chain protecting group is introduced at the acylation position, O N- end of the peptide's main chain is. then, protected by Boc with the use of Boc20 or, alternatively, with the use of an amino acid protected by Boc in the last coupling. Although the peptide is still attached to the resin, the orthogonal lateral bitch protecting group is selectively cleaved with the use of freshly prepared hydrazine hydrate (2 to 4%) in NMP for 2 x 15 minutes. The side chain of the unprotected Plant is, firstly, coupled to Fmcc-GluOtBu or another spacer amino acid, which is deprotected with piperidine and postponed with a lipophilic chemical portion using the peptide coupling methodology, as described above. The abbreviations used are as follows;
ivDde: 1- _(4-i 4-dimetiF2,8 dioxodciohexilideno) 3-methyl-butylamino the Dde: 1 - (4,4-dimethyl-2 _I-8 dloxocídohexilideno) -atila DCM: dichloromethane
DMF: N, N-dimethyltormamide DIP EA: diisopropyl ethyl amyl EtOH: ethanol Et2Q: diethyl ether
HATU; N - ((dimethylamino) -iH1,2 _; 3tnazol [4,5-b] pyridine-1-ylmethylene] N-methylmethanamino N-oxide MeCN: acetonitrile
NMP: N-methylpyrrolidons TFA: trifluoroacetic acid
56/66
TIS: triisopropylsilane
CWagem [206] The resin was washed with EtOH (3x10 ml) and Et20 (3x10 ml) and dried until reaching a constant weight at room temperature (r.t.). The crude peptide was cleaved from the resin by treatment with TFA / TIS / water (95 / 2.5 / 2.5; 40 ml, 2 hours; ta ,,) or TFA / DODT (95/5; 40 ml, 2 hours; Most of the TFA was removed under reduced pressure and the crude peptide was precipitated and washed three times with diethyl ether and dried until it reached a constant weight at room temperature.
Purtf / uaçea porHPtC from raw papáWo [201] The raw peptide was punctuated in approximately or more than 90% through preparative HPLC in reverse phase using a PerSeptive Biusystems VISION Workstation workstation equipped with a Ci 8 column (5 cm: 10 pm) and a fraction collector and moved at 35 ml / min with a gradient of buffer A (0.1% TFA, aq.) and buffer B (0.1% TFA, 90% MeCN, aq.). The fractions were analyzed using analytical HPLC and MS and relevant fractions were grouped and lyophilized. The final product was characterized by HPLC and MS.
[202] Fmoc-protected amino acids were purchased from Advanced ChemTech (ACT) in suitable side-chain protected forms.
Coupling Reagents [203] Diisopropylcarbodiimide coupling reagents (DIG) were purchased from Riedel de-Haen, Germany.
So / À / os supports [204] Peptides pierce synthesized in TentaGel S resins from 0.22 to 0.31 mmol / g, TentaGel S-Rams, TentaGel S RAM4.ys (Boc) Fmoc (Rapp Polymere, Germany) used in cases where a C-terminal amidated peptide was preferred, whereas TentaGel S PHB. for example., TentaGel S PHB Asp (Boc) Fmoc were used when an oarboxylic acid
57/66 free C-terminat was preferred.
[205] Asp deprotection (for example, at position 15) was performed with the use of 0.1 M formic acid in 30% Piperidine / NP when the amino acid at the next position (eg position 16) was Gly and there was no heating during synthesis or deprotection.
Cata // sadoros to other roagenfes [206] Diisopropylethylamine (DIEA) was purchased from Aldrich. Germany, piperidine and pyridine next to Riedel-de Hàen, Frankfurt, Germany. Etandythiol was purchased from Riedel-de Hâen. Frankfurt, Germany. 3.4 dihydro-S-hydroxy-α-oxo-1,2,3-benzotriazine (Dhbt-OH) and 1-hydroxybenzutriazcl (HOBt) (HOAt) were obtained from Fluka, Switzerland.
Scop / amaufo procedures [207] The amino acids were coupled as esters of HObt or HOAt generated tn s, it was produced from appropriate Nro-protected amino acids and HObt or HOAt by means of DIC in DMF. The aciiações were verified by the ninldrina test carried out at 80 ^to C in order to prevent the deprotection of Fmoc during the test (Larsen, BD and Holm, A. ,, Inf. J, Peptide Protein Res. 43, 1994, 1 to 9) .
Offspring of the Nro-ammo protecting group (Fmoc)
HPLC purification of the crude peptide [208] The crude peptide products were purified by PerSeptive Biosystems VISION Workstation ,. VISION 3.G software was used for instrumental control and data acquisition. The following column and the HPLC buffer system were used:
Column: Kromasll KR 1Q0Â, 10mm C-8, 250 x 5Ô.8mm.
Buffer system: Buffers: A: 0.1% TFA in MOV; B: 0.065% TFA, 10% MQV, 90% MeCN.
Gradient: 0 to 37 min. 0 to 40% B
Flow 35 ml / min, UV detection: I ~ 215 nm and 280 nm. fepscfrosoop / a of dough
58/66 [2Õ9] The peptides were dissolved in super gradient methanol (Labscan, Dublin, Ireland), milli-Q water (Millipore, Bedford, MA) and thermal acid (Merck, Damstadt, Germany) (50: 50: 0, 1 in v / v / v) to produce concentrations between 1 and W mg / ml. The peptide solutions (20 ml) were analyzed in positive polarity mode by ESI-TOF-MS using a LOT mass spectrometer accuracy (Micrommass, Manchester, United Kingdom) of +/- 0.1 m / z , [210] After purification using preparative HPLC, as described above, the peptide product was collected and the identity of the peptide was confirmed by ES-MS. This procedure was used for the synthesis of all the peptides exemplified below.
Compounds without liver [211] The compounds in Table 1 were synthesized using the above techniques.
Table 1: Synthesized compounds
I Compound | Sequencing | 'i ............................. j Hy-H -Ãib-DQSfedemntíldímqããr ^ | 2 i'h ^ HGDGS ^ DI ^) | 3 ............................ [h ^ HGDGS ^^) faith ......... .................. pHy-H ^ I | 8 ......................... .. 'rHy - HGEGTFTSDLSKQMEGQAVRDREWÜQTKlTDOHi [~ 8 ..... rHy-HGEGTFfSDLSKQ ^ | (7 rHy''HGDGSFSSELAflLDGKAARDFÍNWÜÕfíCfQ'OH |: 8 rHy-HGÊGfn ^ lSTÍLENkÃÃRDFÍEWÜQTKíTf> ÕH |
Pg ............................ f'Hy-HGEGSFSSD ^^ |
ΓΪ0 ........................ [Hy-H-A ^ I
ΓΠ .......... [Hy-HGDGSFSSEl ^ | | 'Ϊ2 rHy-HGDGSFSDÈMNflLDGQ ^ RDRWUQTOiH ^ |
ΓΪ3 ........................ |
Example 1. Synthesis of compound 12
59/66 [212] Solid phase peptide synthesis was performed on a Liberty Peptide Synthesizer available from CEM using standard Fmoc chemistry. TentaGel S Ram S resin (1.33 g; 0.25 mmo / g) was swollen in DMF (10 m ) Before use and transferred between the tube and the reaction vessel using DCM and DMF.
Acop / amento [213] A Fmoc-amincacid in DMF / DCM (2: 1; 0.2 M; 5 ml) was added to the ream in a Discover microwave unit available from CEM from COMU / DMF (0 , 5 M; 2 ml) and DIPEA and DMF (2.0 M; 1 ml). The coupling mixture was heated to 75 ^W C for 5 minutes while nitrogen was bubbled through the mixture. The resin was then washed with DMF (4 x 10 ml). The pseudoproaline Fmoc-Phe-Ser (Psi Me, Me, Pro) -OH was used for the amino acid number six and seven.
Deprotection [214] Pipendin / DMF (20%; 10 ml) was added to the resin for initial deprotection and the mixture was heated by microwave (30 seconds; 40 "C). The reaction vessel was drained and a second portion of pididine / DMF (20%: 10 ml) was added and heated (75 ^<; C: 3 minutes) again. The resin was. then, washed with DMF (8 x 10 ml).
[215] The resin was washed with EtQH (3x10 ml) and Et20 (3x10 ml) and dried until reaching a constant weight at room temperature (La.). The crude peptide was cleaved from the resin by treatment with TFA / DODT (5/5; 80 ml, 2 hours; r.t.). Most of the TFA was removed under reduced pressure and the crude peptide was precipitated and washed three times with diethyl ether and dried until it reached a constant weight at room temperature.
[216] HPI C puncture of the peptide ot [217] The raw peptide fot first, purified by 45% by preparative HPLC, in reverse phase using a PerSeptive Biosystems VISION Workstation workstation equipped with a Gemini NX 5p column C-18 110A, 10x250 mm, and a fraction collector and moved at 35 ml / min
60/66 is a gradient of buffer A (0.1% TFA, aq.) And buffer B (0.1% TEA, 90% MeCN, aq.). The tractions were analyzed by analytical HPLC and MS and relevant fractions were grouped and lyophilized. The product (143 mg) was purified a second time with a 12x25 cm C4 Jupiter 2 column to produce 27 mg, with a purity of 89% as characterized by HPLC and MS. MW (molecular weight) mcnoisotôpíca calculated - 3377.61 ₁ found 3377.57.
Example 2. GLP-2 receptor efficacy assays [218] An AlphaScreen® 'cAMP assay available from Perkin Elmer was used to quantize a cAMP response to a GLP-2 analog. Taduglutlda was the reference compound in that assay and has an EC _&; approximately 0.01 nM. The test compounds that induced an increase in the intracellular level of cAMP were tested in that assay, and the response was normalized to a positive and negative control to calculate the EC4 and the maximum response, from the concentration response curve. The results are listed in Table 2.
Çfe Generation Ce / u / argue expression expresses human GLP-1 receptors [219] The cDNA encoding the human glucagon-like peptide 1 receptor (GLP-1 R) (primary accession number P43220) has been cloned from the cDNA 8C112126 (MGC: 138331 /IM.AGE:8327594). The DNA encoding GLP-1-R was amplified by PGR using primers that encode terminal restriction sites for subulonation. The 5 'end primers further encoded an almost Kozak consensus sequence to ensure efficient translation. The fidelity of the DNA encoding GLP-1 -R was confirmed by DNA sequencing. POR products encoding GLP-1-R stick subcloned into a mammalian expression vector that contains a neomycin resistance marker (G418). The mammalian expression vectors encoding GLP-1-R were transfected into HEK2.93 cells by a standard calcium phosphate transfection method. 48 hours after transfection, cells are seeded for
61/86 cloning by limited dilution and selected with 1 mg / ml of G418 in the culture model. Three weeks later, 12 surviving colonies of cells expressing GLP-i-R were selected, propagated and tested in the GLP-1 receptor efficacy assays, as described below. A clone expressing GLP-1-R was selected by compounding.
[220] Generation of a cell line that expresses GLP-2 humane receptors [221] PGLP2-R was acquired from MRO-Geneservíce, Babraham, Cambridge, as a clone Image: 5363415 (11924-117). For subcloning in a mammalian expression vector, the subcloning injectors are obtained from DNA-Technology, Rísskcv, Denmark. The Inicladeres in 5 ^! and 3 ^: used for the PCR reaction include terminal restriction sites for cloning and the 5 'primer context is modified to a Kozak consensus without changing the sequence of the ORF-encoded product. A standard POR reaction was performed using clone image 5363415 (11924-117) as a model with the aforementioned iniclader and Pulimerase Herculase II Fusion in a total volume of 50 pi. The PCR product generated was purified using of GFX PCR and gel band purification kit, digested with restriction enzymes and cloned into the mammalian expression vector using the ONA Fast Binding Kit. The binding reaction was transformed into Ultra-Competent XL1Q Gold cells and colonies were selected for DMA production using the Endofree Plasmid Maxi kit, The subsequent sequence analysis was conducted by MWG Eurofins, .Germany. The clone was confirmed as the hGLP-2 receptor, splice variant $ 17881884.
[222] HEK293 cells were transfected using the Lipofectamine PLUG transfection method, IM the day before transfection, HEK293 cells were seeded in two T75 flasks at a density of 2x1 cells / T75 flask in cell culture medium without antibiotics . On the day of the transfection. the cells were washed with 1x DPBS and the medium was replaced
62/68 with Optimem up to a volume of 5 ml / T75 vial before the addition of plasmid-Upofectamine complexes which was added slowly and in drops to the cells in T75 vials and replaced with growth medium after 3 ivy and again to the growth supplemented with 500 pg / ml of G418 after 24 hours. After 4 weeks in G418 selection, the colonies were selected and tested in a functional assay. One colony was selected for use in profiling compost.
GLP-1 receptor scavenging assays [223] The AlphaScreen® cAMP assay available from Perkin Elmer was used to quantize the cAMP response to GLP1 and GLP2 receptor activation, respectively. Exendin-4 (ZP24) was used as a reference compound for GLPi receptor activation and Teduglutide (ZP1559) as the reference compound for GLP2 receptor activation. The data of the test compounds that induce an increase in the intracellular level of cAMP were normalized in relation to the positive and negative control (vehicle) to calculate the EC® and the maximum response from the concentration response iv. The results were listed in Table 2.
[224] Table 2: EC® measurements of GLP-1 and GLP-2
Composed i String EC® of EC® of i GLP-2R GLP-1 R (Nm) (Nm) GLP-1> 1000 0.01 GLP-20.06 > 200/1000 (Giys) T 1 | Hy-H-Aib- 0.12 44| DGSFSDEMNTILDNQAARDPINWU | QTKITD-OH 2 I Hy- f () <02 .............. '77| HGDGSFSDEMNTILDNKAARDFINW I LIQTKITD-OH
63/66
Composed
Sequence
ECO of ^ξ ECso of
GLP-2R -GLP-1R | 3 (Mm) (Nm)
Hy ~
HGDGSFSDaWILDGQAARDRN; WUQTK-NHg i HvHGDGSFSSEMNTILDSQAARDFINW
UQTKITD-OH
HyHGEGTFTSDLSKQMEGQAVRDFIE
WUQTKITD-OH
HyHGEGTFTSDLSKQMESKAARDFIE i WLIQTKÍDT-OH
HyHGDGSFSGELAIÍLOGKAARDFINW
UQTKITD-GH
HvHGEGTFTSDLSTILENKAARDREWl
IQTKITD-OH | _H yi HGEGSFSSDLSTÍLENKAARDFÍEWL
IQTK.ITD-OH
Hy-H-AibDGSFSDELNTILDGKAARDAMWLIQ
TK-NHg
HyHGDGSFS3 FLAT t uÜGQAARDFÍ AW
QTKiTDOH
0.07
0.06
0.2
0.2
0.2
0.73
0.008
0.2
9.10
03
64/66
i Campaste j Sequence I EC§ of j EC ^ of I| | GLP-2R | GLP-1Rj j (Mm) j (Nrn) i 12 | Hy ~ | 9.0 i 0.07| HGDGSFSDEMNTILDGQAARDFIN | |I WLIQTK-NHg | | : | 13 I Hy- I 0.1 1 18 j| HGEGSFSSDLSTILEGKAARDFiEW J [í1 LiQTKiTD-OH i í 1
Example 3: Effect on glucose tolerance in normal rats [226] Male C57SL / 6J normal mice on a standard diet were used. The mice were kept in standard housing conditions (environment under controlled light, temperature and humidity (light-dark cycle of
12:12 h, with I uz.es on from 6 am to 6 pm: 24 ° C; 50% relative humidity)), and
each dosing group consisted of 1G animals.
[226] Before an oral glucose tolerance test (OGTT), the animals were fasted for 6 hours. One hour before the glucose test (time t ~ -60 min), baseline blood glucose is such a measure. Immediately after the blood sample, the animals received the dose once, subcutaneously, of the compound in the indicated amount or PSS (vehicle). One hour later at ~ 0 min, an oral gavage of 2 g / kg of glucose (0.4 g / ml in water diluted from glucose SAD 0.466 g / 1; dose volume of 5 ml / kg) was given to animals. After the administration of glucose, blood from the tail vein was drawn for glucose measurements at t ~ 15, 30.60, 120 min.
Results [227] The vehicle-treated mice showed a typical response to the glucose test, with an increase in blood glucose levels in the first 30 minutes, followed by a return to baseline levels after 120 minutes. The test compound significantly reduced the blood glucose response (Figure 2).
65/66
Example 4: Effect on intestinal peon in normal mice [228] The normal male Wistar mice on a standard diet were fed. The mice were kept in standard housing conditions (environment with controlled light, temperature and humidity (12:12 h elaro-dark cycle, with lights on from 8 h to 18 h; 24 'C: 50% relative humidity) ), and each dosage group consisted of 6 animals. The mice received the dose once a day through the subcutaneous route, for four days with the compound in the indicated amount or PBS (vehicle). On the fifth day, the mice were sacrificed and the wet weight of the small intestine was measured.
Results (229] The test compound increased intestinal weight in a dose-dependent manner (Figure 3).
Example 5: Effect of compound 7 in mice with distal-induced obesity [23Ô] Diet-induced obesity was generated by feeding male C57BL / 6J mice with a high-fat diet (Research Diet with 60% fat (012492) available from Research Diet Inc., New Brunswick, USA). The mice were kept in standard housing conditions (environment with controlled light, temperature and humidity (light cycle. Dark 12:12 h, with lights on from 6 h to 18 h: 24 ^to C; 50% relative humidity) ).
(231] The vehicle-treated dosing group contained 8 animals and the groups treated with the compound / consisted of 12 animals / group. All animals were treated with mock cells for 7 days (once daily, SC, 100 µl of vehicle) to adapt animals to handling and injections, followed by treatment (with vehicle or compound 7) for 14 days (twice daily, SC <5 ml / kg). Animals were fasted for one overnight (day 11-12) and blood was drawn for analysis of glucose and insulin .. On day 14 .. the animals were sacrificed and the small intestines βδ / 66 large were removed, washed and weighed.
Results [232] Compound 7, at a dose of twice a day for 14 days, significantly increased the mass of the small and large intestine when compared to vehicle-treated controls (Figure 4).
[233] Compound 7, at a dose of twice a day for 14 days, reduced plasma insulin and fasting blood glucose levels, and produced a lower HOMA-IR index than vehicle-treated controls (Figure 5) .
[234] Although the invention has been described in conjunction with the exemplary modalities described above, many equivalent modifications and variations will be clear to those skilled in the art when reading this disclosure. Consequently, the exemplary embodiments of the invention established are considered to be illustrative and not limited. Several changes to the described modalities can be made without deviating from the spirit and scope of the invention. All documents cited herein are expressly incorporated into the reference title.

权利要求:
Claims (39)
[1]
1. Anaphoo of GLP-2 caused by being represented by cell W. ΛΜΑΜΛΜΑΜΑΜΛΜΛΜΛΜΛΜΛΜΑΜΑΜΛΜΑΜΑ ^ ΜΑΜΑΝ. f «.
General formula I:
R ⁵ - Hís-X2-X3-Gly-X3-Phe-X7-X8-X9-X10-X11 -X12-X13-X14-X15XI6-X17-Wing-X 19-X20-X21 -Phe-lle-X24 ~ Trp-Leu ~ X27-X28-X29 ~ X30X31-X32X33 X34-R ² (I) or a pharmaceutically acceptable salt or solvate thereof, where:
R ^! is hydrogen, Cva alkyl (for example, methyl), acetite, formyl, benzoyl or trifluoroacetyl;
X2 is Gly, Ala: or Aid;
X3 is Glu, Gin or Asp:
X5 is Ser or Thr:
X7 is Ser or Thr:
X8 is Asp. Glu or Ser:
X9 is Glu or Asp;
XI0 is Met, Vai, Leu eu Tyr:
X11 is Asn, Ser or Ala;
XI2 is Thr, Ser or Lys;
XI3 is ile, Leu, Vai, Tyr, Phe or Gin;
XI4 is Leu or Met;
XIS is Asp or Glu;
XI6 is Asn, Gin, Gly, Ser, Ala, Glu or Lys;
XI7 is Gin, Lys, Arg, His or Glu;
XI9 is Ala or Vai;
X20 is Arg, Lys or His;
X21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys;
X27 is Ile, Leu, Vai, Glu or Lys:
X28 is Gin, Asn, Lys, Ser, Gly, Y1 or absent;
[2]
2/14
X29 is Thr, Ala. Y1 or absent;
X30 is Lys, ΥΊ or absent:
X31 is He, Pro, Y1 or absent;
X32 is Thr, Y1 or absent;
X33 is Asp, Asn, Y1 or absent;
I saw O Gly-Gly-Pro-Ser-Ser-Gly Ala-Pro-Pro-Pro-Ser, I Lys-Ásn-GlyGly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; and
R ² is NH ₂ or OH; wherein the GLP-2 analogue contains no more than one Y1;
if any of X28 through X33 is ¥ 1, those positions X29 through X34 downstream from that Y1 are absent;
if any of X28 to X33 is absent, those positions X29 to X33 downstream from that position are also absent; and as long as the Formula I GLP-2 analogue is not
HGDGSFSDEMNTILDGQAARDFIMWUQTKITD;
HGDGSFSDEMNTILDNQAARDFINWLIQTKITD; or
HGDGSFSDEMNTILDSQAARDFINWUQTK.
Analog of GLP-2 or a pharmaceutically acceptable salt or solvate thereof, according to claim 1, characterized by:
Ff be hydrogen,
X2 is Gly, Ala or Aib;
X3 is Glu, Gin or Asp;
XS is Ser or Thr;
X7 is Ser or Thr;
X8 is Asp, Glu or Ser;
X9 is Glu or Asp;
XI0 is Met, Val, Leu or Tyr;
X11 be Ace or Ser;
X13 is lie, Leu, Val, Tyr, Phe or Gin;
X14 is Leu or Met;
[3]
3/14
XI2 be Thr or Lys:
XI5 is Asp or Glu;
XI8 be Asn, Gin, Gly, Ser, Ala, Glu or Lys:
XI7 be Gin or Lys:
XI9 be Wing or Val:
X2Q is Arg, Lys or His;
X21 be Asp, Glu or Leu:
X24 is Aso, Ala, Glu or Lys;
X27 be He, Leu, Vai or Lys:
X28 being Gin, Asn, Gly, Y1 or absent;
X28 Ser Thr, Ala, ¥ T bu absent:
X30 be Lys, Y1 or absent:
X31 is He, Pro, Y1 or absent;
X32 is Thr, ¥ 1 or absent;
X33 be Asp. Asn, ¥ 1 or absent;
¥ 1 ser -Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser;
and
R ² is NHg or OH; where the GLP-2 analogue contains no more than one ¥ 1;
if any one of X28 to X33 is Y1, those positions X29 to X34 downstream of that Y1 are absent;
if any of X28 to X33 is absent, those positions X29 to X33 downstream from that position are also absent: and as long as the GLP-2 analog of Formula I is not
HGDGSFSDEMNTILDGQAARDFINWUQTKITD;
HGDGSFSDEMNTILDNQAARDFINWLIQTKITD; or
HGDGSFSDEMNTILDSQAARDFINWLIQTK.
3. GLP-2 analogue characterized by being represented by the general Formula Ia:
R ^! - His-X2-X3 ~ Gly-X5-Phe-X7-X8-X9 ~ X10-X11 -XI 2-X13-Leu-X15
[4]
4/14
XW-X17-Alia-Ala-X20 ~ X21 ~ Phe4le'X24-T P-Leu-X27> X28-X29-X30-X31-X32X33-R '· (la) eu is a pharmaceutically acceptable salt or solvate thereof, on what:
R 'is hydrogen, CY * alkyl (eg media), acedia, formlla, benzoyl or trifluoroacetyl:
X2 is Gly, Ala or Aíb:
X3 is Glu, Gin or Asp;
XS is Ser or Thr;
X7 is Ser eu Thr;
Shah is Asp, Glu or Ser:
X9 is Glu or Asp;
X10 is Met, Val, Leu or Tyr;
X11 is Asn or Ser:
XI2 is Thr, Ser or Lys;
X13 is He, Leu, Vai, Tyr, Phe or Gin;
X15 is Asp or Glu:
X16 is Asn, Gin, Gly, Ser, Ala, Glu or Lys;
X17 is Gin, Lys, Arg, Hls or Glu;
X20 is Arg, Lys or Hls:
X24 is Asn, Ala, Glu or Lys;
X27 will lie, ueu, Vai, Glu or Lys:
X28 is Gin, Asn, Lys, Ser, Gly, Y1 or absent;
X29 is Thr, Y1 or absent;
X30 is Lys, ΥΊ or absent;
X31 is He, Pro, Y1 or absent;
X32 is Thr, Y1 or absent;
X33 is Asp, Asn, Y1 or absent;
¥ 1 is Gíy-Gly-Pro-Ser-Ser-Gly-Ata-Pro Rro-Pro-Ser;
[5]
5/14 and
R '· is nu OH; wherein the GLP-2 analogue contains no more than one Y1;
if any of X28 to X33 is ¥ 1, those positions X29 to X34 downstream from that Y1 are absent:
if any of X28 to X33 is absent, those positions X29 to X33 downstream from that position are also absent; and as long as the Formula 1 GLP-2 analogue is not
HGDGSF8DEMNTILDGQAARDFINWLIQTKITD;
HGDGSFSDEMNTILDNQAARDFINWUOTK1TD; or hGDGSF S-DE.MN 1 ILDSQAARLE 'tNW liQ 1 K,
4. Analog of GLP-2 or pharmaceutically acceptable salt or solvate thereof, according to claim 3, which is oxygenated by
R ’be hydrogen,
X2 is Gly, Ala or Aib;
X3 is Glu, Gin or Asp;
X5 is Ser or Thr;
X7 is Ser or Thr;
X3 is Asp, Glu or Ser;
X9 be Glu I Asp:
XI0 be Met, Vai, Leu a r Tyq
X11 be Asn or Ser;
X12 be Thr or Lys:
XI3 be lie, Leu, Vai, Tyr, Pbe or Gin:
XI5 be Asp or Glu:
X16 be Asn, Gin, Gly, Ser, Wing, Glu or Lys:
XI7 be Gin or Lys;
X20 is Arg, Lys or His;
X21 be Asp, Glu or Leu:
X24 be Asn, Ala, Glu or Lys:
[6]
6/14
X27 is He, Leu, Val or Lys;
X28 be Gin, Ase, Gíy, ¥ 1 or absent:
X29 is Thr, ¥ 1 eu absent;
X30 be Lys, ¥ 1 or absent:
X31 be lie. Pro, Y1 or absent;
X32 is Thr, ¥ 1 or absent;
X33 be Asp, Asn, Yt or absent:
¥ 1 be Gly-Giy-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser; and
R ² is NHj> or OH: where the GLP-2 analog contains no more than one ¥ 1;
if any of X28 to X33 is Y1, those positions X29 to X34 downstream of that ¥ 1 are absent;
if any of X28 to X33 is absent, those positions X29 to X33 downstream from that position are also absent; and as long as the Formula 1 GLP-2 analogue is not
HGDGSFSDEMNTÍLDGQAARDFINWLIQTKITD;
HGDGSFSDEMHTILDNQAARDHNWUGTKITD: or
HGDGSFSDEMNTILDSQAARDFÍNWLIQTK.
A GLP-2 analogue according to any one of claims 1 to 4, characterized in that X17 is Gin.
A GLP-2 analogue according to any one of claims 1 to 4, as long as X17 is Lys,
[7]
A GLP-2 analogue according to any one of claims 1 to 4, characterized in that color XI7 is Giu,
[8]
8. GLP-2 dwarf according to claim 1 or 2, characterized in that XI4 is Leu.
[9]
A GLP-2 analogue according to claim 1 or 2, converted by XI4 to be Met.
[10]
LPG-2 dwarf according to any one of claims 1 to 4. characterized by:
.>> Λ ^ αλλααααλ * λ * λ * λλ * ^ λαλα ^ λ ^ αλλλλλλλαααααΛαααααααλ (Ο XI8 be Gly and X17 be Gin;
(ii) XI 8 is Qiy and XI7 is Lys; I (iii) X18 being Gly and XI7 being Qiu,
[11]
11, LPG analogue - 2, according to any one of claims 1 to 10, characterized in that X2 is Aib,
[12]
12, GLP-2 analogue according to claim 1 or 2, or any of claims Sail as dependent on claim 1 or 2, characterized in that XI9 is Ala.
[13]
13, GLP-2 analogue according to claim 1 or 2, or any of claims 5 to 11 as dependent on claim 1 or 2, characterized in that Xi9 is Val,
[14]
14, Analog of GLP-2 characterized by being represented by the General Formula II:
R «HíS'X2-X3-Gly'X5-PhO'X7-Ser-Glu -Leu-Ala-XI 2-X13-X14-X15X18-X17-Ala-X19-X20-X21-Phe-lie-X24-Trp -Leu-X27 ~ X28-X29-X30-X3bX32 ~ X33-X3-R ² (II) or a pharmaceutically acceptable salt or solvate thereof, where:
R ¹ is hydrogen, C® alkyl (e.g., methyl), acetyl, formyl, benzoyl or trifluoroacetyl;
a '’ <ss · Μ' X-SiA * <
X3 and Giu, Gin or Asp;
X5 is Ser or Thr;
X7 is Ser or Thr;
X12 is Thr, Ser or Lys;
X13 is He, Leu, Val, Tyr, Phe or Gin;
XI4 is Leu or Met;
X1S is Asp or Glu;
XI8 is Gly, Ser, Ala, Glu or Lys;
X17 is Glu or Lys;
8/14
Xi9 is Ala or Vai;
X20 is Arg, Lys or His:
X21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys:
X27 is He, Leu, Vai, Glu or Lys:
X28 is Gia, Aso, Lys, Ser, Y1 or absent;
X29 is Thr, Ala, ¥ 1 or absent:
X30 is Lys, Yl I missing:
X3i is He, Pro, ¥ 1 or absent:
X32 a-Thr ¥ 1 qu absent '
X33 is Asp, Asn, ¥ 1 or absent;
X34 is ¥ 1 or absent;
Yl is Gly-Gly-Pro-Ser-Set-Gly-Ala-Pto-Pro-Pro-Ser, or Lys-Asn-GlyGly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pra-Ser; and
R ^;; - it's NFL I OH; wherein the GLP-2 analog contains no more than one Y1;
if any of X28 through X33 has Y1, those positions X29 through X34 downstream from that Y1 are absent;
if any of X28 to X33 is absent, those positions X29 to X33 downstream from that position are also absent.
[15]
15, Analog of GLP-2, according to claim 14, characterized in that X16 of Formula II is Gly, Ser eu Ala, and epicily XI7 is Lys or Gin.
[16]
16. A GLP-2 analogue according to claim 14, characterized by
R be hydrogen, Cm alkyl (eg methyl), acetyl, formyl, benzoyl and trifluuraoethyl:
X2 is Gly or Aib;
X3 is Glu or Asp;
X5 is Ser or Thr;
9/14
X7 be Ser or Thr:
XI2 is Thr, Ser or Lys;
X13 is He, Leu, Val, Tyr, Phe or Gin;
ΧΊ4 be Leu or Met:
XI5 is Asp or Glu;
X16 be Gly, Ser or Ala:
XI7 be Gin or Lye:
X19 be Ale eu Vai:
X20 and Arg, Lys or Hie:
X21 is Asp, Glu or Leu;
X24 is Asn, Ala, Glu or Lys;
X27 is He, Leu, Val, Glu or Lys;
X28 be Gin, Asn, Lys, Ser, ¥ 1 or absent:
X29 is Thr, Ala, Y1 or absent;
X30 ear Lys, ¥ 1 or absent;
X31 is lie, Pro, ¥ 1 or absent;
X32 is Thr, Y1 or absent;
33 be Asp, Asn, ¥ 1 or absent;
X34 be ¥ 1 or absent:
Y1 be Giy-Gly-Pro-Ser-Ser-Gly-Aia-Pro-Pra-Pro-Ser, or Lys-AsnGíy-Giy-Pru-Sér-Ssr-Giy-Aía-Pm-Pro-Pro-Ser :; and
R ² is NHg or OH; where the GLP-2 analog contains nan mats than a Y1;
if any of X28 to X33 is ¥ 1, those positions X29 to X34 downstream of that ¥ 1 are absent;
if any of X28 to X33 is absent, those positions
X29 to X33 downstream from that position are also absent
[17]
17, Analog of GLP-2, according to any one of claims 14 to 18, characterized by:
(I) X18 if Gly and X17 be Gin; I
10/14 (ii) X16 is Gly and XI7 is Lys.
[18]
18. GLP-2 analog. according to any one of claims 14 to 17, characterized by:
(i) X2 being Gly: c> u (it) X2 being Aid,
[19]
19. Analog of GLP-2 characterized by being represented by General Formula III:
R '-His-Gly-XS-Gly-XS-Phe-XZ-SenGlu-Leu-Ayia-XI2-X13-Leu-Xl 5Gly-XI 7-Ala-X! 9-X20-X21 -Phe-l! E -X24 ~ Trp-Leu ~ X27-X28-X29 ~ X30-X31 -X32 or a pharmaceutically acceptable salt or solvate thereof, where:
R ^; è hydrogen, alkyd (for example, methyl), acetyl, formyl, benzoyl or trifluoruacetyl;
X3 is Glu or Asp;
X5 is Ser or Thr;
X7 is Ser or Thr;
X12 is Thr, Ser or Lys;
X13 is He, Tyr, or Gin;
XI5 is Aap or Glu:
XI7 and Gin or Lys:
XI9 is Ala or Val ·;
X20 is Arg, Lys or His:
X21 is Asp, Glu or Leu:
X24 is Asn, Ala, Glu;
X27 is He, Leu, Glu au Lys:
X28 is Gin, Lys, Ser, Gly, YI or absent;
X29 is Thr. Ala, YI me absent:
X30 is Lys, YI au absent;
X31 is He, Pro, YI or absent;
X32 is Thr, ¥ 1 or absent;
X33 is Asp _s Asm ¥ 1 or. Absent;
X34 is Y1 or absent;
Y1 is Gly-Giy Pre-Ser-Ser-Gly-Aia-Pro-Pro-Pro-Ser, or Lys-Asn-GlyGiy ~ Pro ~ Ser ~ Ser ~ Gly-Aia-Pro-Pro-Pro-Ser; and
R ^; · Is NHg or QH; wherein the GLP-2 analogue contains no more than one Y1;
if any of X28 to X33 is Y1, those positions X29 to X34 downstream of that Y1 are absent;
If any of X28 to X33 is absent, those positions X29 to X.33 downstream from that position are also absent.
[20]
20, GLP-2 analog. according to any one of claims 1 to 19, characterized in that it is selected from
H-AibDGSFSDEMNTILDNQAARDFINWNIQTKITD;
HGDGSFSDEMNTILDNKAARDFINWLiQTKITD;
HGDGSFSDEMNTILDGQAARDFINWLIQTK;
HGDGSFSSEMNTILDSQAARDFINWMQTKITD;
HGEGTFTSDLSKQMEGQAVRDFIEWLIQTKITD;
HGEGTFTSDLSKQMESKAARDFIEWLIQTKITD;
HGDGSFSSELATiLDGKAARDFINWüQTKITD:
HGEGSFSSDLSTILENKAARDFIEWUQTKITD;
H-Aib-DGSFSDELNTILDGKAARDFINWLIQTK;
HGDGSFSSELATILDGQAARDFIAWLIQTKITD;
HGDGSFSDEMNTiLDGQAARDFINWUQTK; and HGEGSFSSDLSTILEGKAARDFIEWLIQTKITD;
or a pharmaceutically acceptable form or solvate thereof.
[21]
21. A GLP-2 analogue according to any one of claims 1 to 20, characterized in that a lipophilic substituent is conjugated to one or more of positions 12, 14,16,17,19, 20,24, 27, 28 and 32.
12/14
[22]
22. A GLP-2 analogue according to any one of claims 1 to 21, characterized in that a lipophilic substance is conjugated to one or more of the positions 12,16,17, 20, 24, 27, 28 and 32.
[23]
23. A GLP-2 analogue according to any one of claims 1 to 22. characterized in that a lipophilic substitutant is conjugated to one or more of positions 16, 17, 20, 2.4, 27, 2.8 and 32.
[24]
24. A GLP-2 analogue according to any one of claims 1 to 23, characterized in that it is for use in therapy,
[25]
25. Pharmaceutical composition, characterized in that it comprises a GLP-2 analogue according to any one of claims 1 to 23. or a salt or derivative thereof, in mixture with a carrier.
[26]
Pharmaceutical composition according to claim 25, characterized in that the GLP-2 analogue is a pharmaceutically acceptable acid addition salt.
[27]
27. Pharmaceutical composition according to claim 25 or 26, characterized in that it is formulated as a liquid suitable for administration by injection or infusion, or because it is formulated to cause a slow release of said GLP-2 analog.
[28]
28. Use of a GLP-2 analogue according to any one of claims 1 to 23, which can be characterized for the preparation of a medicament for the treatment and / or prevention of low-grade inflammation.
[29]
29. Use of a GLP-2 analogue according to any one of claims 1 to 23, characterized in that it is made for the preparation of a medicament for and treatment and / or prevention of low-grade inflammation related to diabetes.
[30]
30. Use according to claim 29, characterized in that low-grade inflammation related to diabetes is associated with:
metabolic syndrome, obesity (eg abdominal obesity), diabetes, cardiovascular disease, gastrointestinal inflammation, depression, Alzheimer's, arthritis, hypertension, dyslipidomy, stroke
Cerebral 13/14; gastrointestinal disorders in the upper gastrointestinal tract of the esophagus, stomach, duodenum, small intestine, colon and rectum, ulcers of any etiologic, digestive disorders, malabsorption syndromes, short bowel syndrome, cul-de-sac syndrome, inflammatory disease intestinal, celiac sprue, tropic sprue, hypugamaglobulinaemia and mucositis sprue and diarrhea induced by chemotherapy and / or hemotherapy therapy,
[31]
31. A nucleic acid molecule characterized in that it comprises a sequence of nucleic acids encoding a GLP-2 analogue according to any one of claims 1 to 20.
[32]
32. çaraçterizadp expression vector for understanding the nuuic acid sequence according to claim 3i in combination with control sequences to direct its expression.
[33]
33 .. Host cell characterized by transforming the expression vector, according to claim 32,
[34]
34. The method for producing the GLP-2 analogue, according to any one of claims 1 to 20, the method being characterized by comprising culturing the host cells, according to claim 33, under conditions suitable for expressing the analogue of GLP-2 and purify the GLP-2 analogue then produced.
[35]
35. The nucleic acid molecule according to claim 31, a host, according to claim 33, osractanzados for being for use in therapy.
[36]
36. Use of a nucleic acid molecule, according to claim 31, an expression vector, according to claim 32, or a host cell, according to claim 33, characterized in that it occurs in the preparation of a medicament for the treatment and / or prevention of low-grade inflammation associated with obesity (eg, abdominal obesity), diabetes, cardiovascular diseases, gastrointestinal inflammation, depression, Alzheimer's, arthritis, hypertension, dyslipidemia, stroke
14/14 brain gastrointestinal disorders in the upper gastrointestinal tract of the esophagus, the stomach. duodenum, small intestine, colon and rectum, including ulcers of any etiology, digestive disorders, malabsorption syndromes, short bowel syndrome, cuLde-sac syndrome, intestinal inflammatory disease, celiac sprue, tropic sprue, hypogammagiobulinemia sprue and mucositis and diarrhea induced by chemotherapy and / or radiation-hemotherapy.
[37]
37. Method characterized by treating a disorder related to the stomach and intestine in a patient who requires it by administering an effective amount of a GLP-2 analog, according to any one of claims ta 23, a molecule of nuosomal acid, according to reiwocagao 31> an expression vector, according to claim 32, or a host cell, according to claim 33.
[38]
38. Method according to claim 37, characterized in that the disorder related to the stomach and intestine is low-grade inflammation associated with metabolic syndrome, obesity (e.g., abdominal obesity), diabetes, heart disease, gastrointestinal inflammation, depression, Alzheimer's, arthritis, hypertension, dyslipidemia. stroke; gastrointestinal disorders in the upper gastrointestinal tract of the esophagus, the stomach, duodenum, the small intestine, colon and rectum, including ulcers of the small intestine, cui-de-sac syndrome, intestinal inflammatory disease, celiac sprue, tropic sprue, hypogammaglobulinemic sprue and munositis and diarrhea induced by chemotherapy and / or radiation-hemotherapy.
[39]
39. Therapeutic kit comprising a chemotherapy drug for cancer and a GLP-2 analogue according to any one of claims ia 23, a nucleic acid molecule according to claim 31, an expression vector, of according to claim 32, or a host cell, according to claim 33, each optionally in combination with a pharmaceutically acceptable carrier.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112014027345A2|2019-09-03|glucagon-like peptide 2 analogs |

---

US11111285B2|2021-09-07|Glucagon-GLP-1-GIP triple agonist compounds

---

US11008375B2|2021-05-18|GIP-GLP-1 dual agonist compounds and methods

---

US10092648B2|2018-10-09|Selective glucagon-like-peptide-2 | analogues

---

BR112019011859A2|2019-10-29|glp-1 / glp-2 double agonist, composition, method for increasing intestinal mass, prophylaxis method or treatment of intestinal malabsorption, and use of a double agonist

---

AU2017371516A1|2019-05-23|Acylated GLP-1/GLP-2 dual agonists

---

WO2018103868A1|2018-06-14|Acylated glp-1/glp-2 dual agonists

---

WO2020098657A1|2020-05-22|Glucagon-derived peptide having dual receptor agonistic action and use thereof

同族专利:

---

公开号 | 公开日

---

CN104540850A|2015-04-22|

---

US20180298077A1|2018-10-18|

---

EP2844670A1|2015-03-11|

---

CN104540850B|2018-05-18|

---

EA028929B1|2018-01-31|

---

EA201491934A1|2015-07-30|

---

US9969787B2|2018-05-15|

---

AU2013255752B2|2017-11-09|

---

TR201802689T4|2018-03-21|

---

MX2014013319A|2015-07-06|

---

US20160355563A1|2016-12-08|

---

AU2013255752A1|2014-12-18|

---

IN2014DN09782A|2015-07-31|

---

JP2015517299A|2015-06-22|

---

US20150125431A1|2015-05-07|

---

MX356958B|2018-06-20|

---

CA2872315A1|2013-11-07|

---

US10253080B2|2019-04-09|

---

WO2013164484A1|2013-11-07|

---

KR20150006052A|2015-01-15|

---

HK1208238A1|2016-02-26|

---

EP2844670B1|2017-12-06|

---

JP6298044B2|2018-03-20|

---

US9453064B2|2016-09-27|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

ZA811368B|1980-03-24|1982-04-28|Genentech Inc|Bacterial polypedtide expression employing tryptophan promoter-operator|

---

JP2961045B2|1993-02-24|1999-10-12|日清製粉株式会社|Intestinal mucosa enhancement promoter|

---

US6184208B1|1994-06-29|2001-02-06|Immunotech Developments Inc.|Peptide, a method for its preparation and a pharmaceutical composition containing the peptide|

---

US5789379A|1995-04-14|1998-08-04|Allelix Biopharmaceutical Inc.|Glucagon-like peptide-2 analogs|

---

US5834428A|1995-04-14|1998-11-10|1149336 Ontario Inc.|Glucagon-like peptide-2 and its therapeutic use|

---

US6184201B1|1995-04-14|2001-02-06|Nps Allelix Corp.|Intestinotrophic glucagon-like peptide-2 analogs|

---

US5990077A|1995-04-14|1999-11-23|1149336 Ontario Inc.|Glucagon-like peptide-2 and its therapeutic use|

---

US5912229A|1996-03-01|1999-06-15|Novo Nordisk Als|Use of a pharmaceutical composition comprising an appetite-suppressing peptide|

---

ES2364705T3|1996-03-01|2011-09-12|Novo Nordisk A/S|APPETITE SUPPRESSOR PEPTIDE, ITS COMPOSITION AND USE.|

---

WO1997039031A1|1996-04-12|1997-10-23|1149336 Ontario Inc.|Glucagon-like peptide-2 analogs|

---

US5994500A|1996-07-19|1999-11-30|1149336 Ontario Inc.|Antagonists of intestinotrophic GLP-2 peptides|

---

US20020025933A1|1996-08-30|2002-02-28|Knudsen Liselotte Bjerre|GLP-2 derivatives|

---

KR100556067B1|1996-08-30|2006-03-07|노보 노르디스크 에이/에스|Glp-1 derivatives|

---

CZ295838B6|1996-09-09|2005-11-16|Zealand Pharma A/S|Process for preparing peptides|

---

US5952301A|1996-12-10|1999-09-14|1149336 Ontario Inc.|Compositions and methods for enhancing intestinal function|

---

CA2236519C|1997-05-02|2011-09-13|1149336 Ontario Inc.|Methods of enhancing functioning of the large intestine|

---

WO1998052600A1|1997-05-16|1998-11-26|1149336 Ontario Inc.|Methods of enhancing functioning of the upper gastrointestinal tract|

---

US6051557A|1997-05-16|2000-04-18|1149336 Ontario Inc.|Methods of enhancing functioning of the upper gastrointestinal tract|

---

EP2574336A1|1998-02-02|2013-04-03|Trustees Of Tufts College|Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism|

---

IL138214D0|1998-03-09|2001-10-31|Zealand Pharmaceuticals As|Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis|

---

WO1999058144A1|1998-05-11|1999-11-18|1149336 Ontario Inc.|Methods of enhancing functioning of the large intestine|

---

US6451987B1|1999-03-15|2002-09-17|Novo Nordisk A/S|Ion exchange chromatography of proteins and peptides|

---

AU3273500A|1999-03-17|2000-10-04|Novo Nordisk A/S|Method for acylating peptides and novel acylating agents|

---

EP1076066A1|1999-07-12|2001-02-14|Zealand Pharmaceuticals A/S|Peptides for lowering blood glucose levels|

---

AU2020501A|1999-12-08|2001-06-18|1149336 Ontario Inc.|Chemotherapy treatment|

---

US7186683B2|2000-09-18|2007-03-06|Sanos Bioscience A/S|Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders|

---

EP1326630B1|2000-09-18|2008-05-28|Sanos Bioscience A/S|Use of glp-2 peptides|

---

US7371721B2|2000-09-18|2008-05-13|Sanos Bioscience A/S|Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes|

---

WO2002066062A2|2001-02-01|2002-08-29|Drucker Daniel J|Enhancement of glp-2 activity|

---

EA006160B1|2001-02-16|2005-10-27|Конджачем, Инк.|Long lasting glucagon-like peptide 2 for the treatment of gastrointestinal diseases and disorders|

---

JP2005506956A|2001-06-01|2005-03-10|イーライ・リリー・アンド・カンパニー|Long-acting GLP-1 formulation|

---

PL376223A1|2002-10-14|2005-12-27|Novo Nordisk As|Glucagon - like peptide - 2 variants|

---

US7411039B2|2002-10-14|2008-08-12|Novo Nordisk A/S|GLP-2 compounds, formulations, and uses thereof|

---

CN1705681A|2002-10-14|2005-12-07|诺沃挪第克公司|GLP-2 compounds, formulations, and uses thereof|

---

KR101241862B1|2003-09-19|2013-03-13|노보 노르디스크 에이/에스|Novel glp-1 derivatives|

---

WO2005082404A2|2004-02-27|2005-09-09|Novo Nordisk A/S|Glp-2 derivatives modified by lipophilic substituents|

---

US7847061B2|2004-11-01|2010-12-07|Nps Pharmaceuticals, Inc.|Treatment of short bowel syndrome patients with colon-in-continuity|

---

NZ591178A|2005-05-04|2012-06-29|Zealand Pharma As|Glucagon-like-peptide-2 analogues|

---

CA2669806C|2006-11-08|2018-10-02|Zealand Pharma A/S|Selective glucagon-like-peptide-2 analogues|

---

AU2008365555B2|2008-12-15|2016-01-14|Zealand Pharma A/S|Glucagon analogues|

---

UY33462A|2010-06-23|2012-01-31|Zealand Pharma As|GLUCAGON ANALOGS|

---

EP2710031B9|2011-05-18|2018-02-28|Mederis Diabetes, LLC|Improved peptide pharmaceuticals for insulin resistance|

---

US9453064B2|2012-05-03|2016-09-27|Zealand Pharma A/S|Glucagon-like-peptide-2 analogues|CA2669806C|2006-11-08|2018-10-02|Zealand Pharma A/S|Selective glucagon-like-peptide-2analogues|

---

US9453064B2|2012-05-03|2016-09-27|Zealand Pharma A/S|Glucagon-like-peptide-2analogues|

---

AR092925A1|2012-10-09|2015-05-06|Sanofi Sa|DERIVATIVES OF EXENDINA-4 AS DUAL AGONISTS OF GLP1 / GLUCAGON|

---

CN104870009B|2012-12-21|2021-05-18|赛诺菲|Functionalized exendin-4 derivatives|

---

US9988429B2|2013-10-17|2018-06-05|Zealand Pharma A/S|Glucagon analogues|

---

DK3057984T3|2013-10-17|2018-10-08|Zealand Pharma As|ACYLED GLUCAGON ANALOGS|

---

US10131702B2|2013-11-06|2018-11-20|Zealand Pharma A/S|Glucagon-GLP-1-GIP triple agonist compounds|

---

MX2016005556A|2013-11-06|2016-07-15|Zealand Pharma As|Gip-glp-1 dual agonist compounds and methods.|

---

TW201609796A|2013-12-13|2016-03-16|賽諾菲公司|Non-acylated EXENDIN-4 peptide analogues|

---

TW201609797A|2013-12-13|2016-03-16|賽諾菲公司|Dual GLP-1/glucagon receptor agonists|

---

WO2015086731A1|2013-12-13|2015-06-18|Sanofi|Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists|

---

TW201609795A|2013-12-13|2016-03-16|賽諾菲公司|EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists|

---

WO2015086729A1|2013-12-13|2015-06-18|Sanofi|Dual glp-1/gip receptor agonists|

---

TW201625668A|2014-04-07|2016-07-16|賽諾菲公司|Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists|

---

TW201625670A|2014-04-07|2016-07-16|賽諾菲公司|Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4|

---

TW201625669A|2014-04-07|2016-07-16|賽諾菲公司|Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4|

---

US9932381B2|2014-06-18|2018-04-03|Sanofi|Exendin-4 derivatives as selective glucagon receptor agonists|

---

CA2965732A1|2014-10-29|2016-05-06|Zealand Pharma A/S|Gip agonist compounds and methods|

---

US20180280480A1|2014-10-31|2018-10-04|Gubra Aps|Compositions and peptides having dual glp-1r and glp-2r agonist activity|

---

ES2763329T3|2015-04-16|2020-05-28|Zealand Pharma As|Acylated glucagon analog|

---

AR105319A1|2015-06-05|2017-09-27|Sanofi Sa|PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR|

---

AR105284A1|2015-07-10|2017-09-20|Sanofi Sa|DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS|

---

KR20180096733A|2015-12-23|2018-08-29|더 존스 홉킨스 유니버시티|A long-acting GLF-1R agonist as a treatment for the nervous system and neurodegenerative conditions|

---

JP6700150B2|2016-10-03|2020-05-27|東京エレクトロン株式会社|Particle collecting device, particle collecting method, and particle collecting system|

---

WO2018104558A1|2016-12-09|2018-06-14|Zealand Pharma A/S|Acylated glp-1/glp-2 dual agonists|

---

WO2018104559A1|2016-12-09|2018-06-14|Zealand Pharma A/S|Glp-1/glp-2 dual agonists|

---

WO2018103868A1|2016-12-09|2018-06-14|Zealand Pharma A/S|Acylated glp-1/glp-2 dual agonists|

---

SG10201911851VA|2016-12-09|2020-02-27|Zealand Pharma As|Acylated glp-1/glp-2 dual agonists|

---

BR112019011859A2|2016-12-09|2019-10-29|Zealand Pharma As|glp-1 / glp-2 double agonist, composition, method for increasing intestinal mass, prophylaxis method or treatment of intestinal malabsorption, and use of a double agonist|

---

RU2019142586A|2017-06-16|2021-07-16|Зилэнд Фарма А/С|DOSING SCHEMES FOR THE ADMINISTRATION OF ANALOGUES OF GLUCAGON-LIKE PEPTIDE 2 |

---

WO2020020904A1|2018-07-23|2020-01-30|Zealand Pharma A/S|Therapeutic uses of glp-2 agonists|

---

EP3924369A1|2019-02-11|2021-12-22|OPKO Biologics Ltd.|Long-acting glp-2 analogs|

---

WO2020249782A1|2019-06-14|2020-12-17|Zealand Pharma A/S|Pharmaceutical parenteral composition of dual glp1/2 agonist|

法律状态:
2019-11-12| B07D| Technical examination (opinion) related to article 229 of industrial property law|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2020-10-20| B07E| Notice of approval relating to section 229 industrial property law|

---

2020-11-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure|

---

2021-02-23| B11B| Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements|

优先权:

---

申请号 | 申请日 | 专利标题

---

US201261642447P| true| 2012-05-03|2012-05-03|

---

US201361785852P| true| 2013-03-14|2013-03-14|

---

PCT/EP2013/059320|WO2013164484A1|2012-05-03|2013-05-03|Glucagon-like-peptide-2analogues|

---